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ABSTRACT 
Introduction: Atrial fibrillation (AF) is a very common condition that causes cardiac 
rhythm disturbance and affects 2.7 to 6.1 million individuals in the United States (US).  
Warfarin, which is considered as a gold standard anticoagulant for the last 50 years to 
treat AF has limitations pertaining to the risk of bleeding, interaction with drugs and 
requires frequent monitoring. Novel Oral Anti-Coagulants (NOAC including dabigatran 
and rivaroxaban) are new promising drugs which have shown better or similar efficacy to 
lower stroke risk and fewer side effects compared to warfarin in the clinical trials.  To 
compete with warfarin, NOACs may need to demonstrate substantial real-world evidence 
in regards to improving clinical outcomes and cost savings.   
Objective: 
The study was designed to evaluate the extent of undertreatment (adherence), and its 
predictors along with the impact of adherence on clinical outcomes, including ischemic 
stroke, bleeding, and Deep Vein Thrombosis and Pulmonary Embolism (DVTPE). 
Furthermore, the analysis helped to estimate the economic burden of NOACs vs. warfarin 
and identify specific subgroups with high-cost drivers and Healthcare Resource 
Utilization (HCRU) to achieve optimal benefits and devise strategies for cost-savings. 
The objective was achieved by conducting the following studies:  
Study 1 - To examine patterns of medication adherence (measured by Proportion of Days 
Covered [PDC]) in patients with atrial fibrillation taking NOACs vs. warfarin for 6 or 12 
months (post index).  Furthermore, the study examined the short and long-term factors 
predicting adherence to the NOAC therapy after controlling potential confounders.  
  
Study 2 - To examine the impact of adherence on the short and long-term risk of ischemic 
stroke, bleeding DVTPE and recurrent DVTPE in patients with AF taking NOACs during 
a one-year period (post index).  The impact of adherence on outcomes was investigated 
by comparison of risk among propensity-matched adherence (adherent vs. non-adherent) 
cohorts. 
Study 3 – To describe and compare the economic burden (cost and HCRU) in patients 
using NOACs vs. warfarin therapy. Furthermore, the study aimed to identify specific 
subgroups and key drivers of high-costs and HCRU. The final aim of the study was to 
explore if there are any differences in cost/HCRU between adherent and non-adherent 
NOAC patients.  
Methods: The research utilized a retrospective cohort study design.  Atrial fibrillation 
patients (ICD-9-CM codes 427.31/32), with ≥2 prescription fills for NOAC or warfarin, 
CHA2DS2VASC score ≥1, and 6-months pre-index continuous enrollment from the 
Optum® Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) (Jan 1, 2010 and 
Dec 31, 2012) were included.  The index date was the first prescription claim for NOAC 
or warfarin. Adherence was calculated using Proportion of Days Covered (PDC) over a 
1-year period.  Predictors of adherence (PDC ≥ 80%) were examined using a logistic 
regression model controlling for the covariates including age, gender, stroke risk, co-
morbidities, insurance type, region, pre-index cardiac drug use (beta-blocker, 
Angiotensin II receptor blockers [ARB] or Angiotensin-converting enzyme [ACE] 
inhibitor, statin), etc.  For the second study, adherent (PDC ≥ 80%) and non-adherent 
patients were matched on the above covariates using propensity score (Inverse 
Probability Treatment Weighting).  The adjusted risk estimates were obtained at 6 and 12 
  
months using a Cox proportional hazards model or generalized linear models (Poisson, 
negative Binomial) and compared across adherence based matched cohorts.  In the final 
study, the economic value in terms of adjusted healthcare costs (inpatient, outpatient, and 
drug costs) and HCRU was estimated using a GLM model with gamma distribution and 
compared between patients taking NOACs vs. warfarin. Unadjusted costs were presented 
using descriptive analysis by subgroups based on demographic and clinical characteristics 
(age, gender, Charlson’s comorbidity index (CCI), insurance type, CHA2DS2VASC 
score, region, pre-index cardiac drug use, including beta-blocker, ARB-ACE inhibitor, 
statin use).  Cost specific to bleeding events were calculated as an exploratory analysis. 
Similarly, the costs and HCRU were descriptively compared between the adherent and 
non-adherent patients taking NOACs. 
Results: A total of 5057 (N=1770 NOAC vs. N=3287 warfarin) patients with mean age 
of 66 years were included in the cohort based on the inclusion and exclusion criteria.  For 
a 12-month follow-up, the proportion of adherent (PDC ≥80%) patients were higher 
among NOACs users (78.42%) compared to warfarin users (61.88%). Using multivariate 
logistic model controlling for the confounders; Age, CCI and statin use were major 
predictors of both short (6-month) and long-term (12-month) adherence to NOACs.  The 
CHA2DS2VASC score was significantly associated with the short-term adherence while 
but not associated with the long-term adherence. 
For 12-month of adherence assessment, the three cohorts for bleeding, ischemic stroke, 
and DVTPE included 1617, 1651, 1739 patients (N=3440 for recurrent DVTPE at 6-
month assessment). For 12-month drug use, the incidence of bleeding, ischemic stroke, 
and DVTPE was 4.21%, 3.11%, and 1.11% respectively. Based on the multivariate 
  
analysis at 6 and 12 months of adherence assessment, the non-adherence was 
significantly associated with 1.72 and 1.94 times increase in the stroke risk respectively. 
Similarly, non-adherence was found to be significantly associated with elevated risk of 
recurrent DVTPE 3 and 6 months and DVTPE risk at 3, 6, 9 months.  The risk of 
bleeding in non-adherent patients was slightly lower (HR= 0.84 – 6 months, HR= 0.94 – 
12 months) but not significant compared to the risk of bleeding in adherent patients.  
High annual drug cost for NOAC users ($4988 vs. $331) was offset by higher medical 
(inpatient and outpatient) costs for warfarin users (Total annual cost for warfarin $31,400 
vs. $22,134). The mean of annual ER visits (14 vs. 13) and office visits (76 vs. 49) was 
also higher for warfarin users compared to the patients taking NOACs.  
Overall, among warfarin users, female patients had higher HCRU, patients from the 
South had higher medical costs and office visits. Highest cost drivers for drug cost for 
warfarin users was patients from Northeast. Conversely, highest cost drivers for medical 
cost were patients less than <65 years and patients with CCI +3.  
For NOACs, the highest cost driver for the drugs was user who were 65 and above, from 
Northeast, CHA2DS2VASC >2 (mod-high risk), and independent insurance. Additionally, 
medical cost was driven by EPO insurance and CCI+3.  
 
Although medical costs and HCRU were lower for adherent vs. non-adherent patients 
taking NOACs, the differences were non-significant. 
Conclusion: Use of NOACs due to its better adherence compared to warfarin may help 
prevent inadequate anticoagulation and complications. Determining the factors 
influencing the adherence such as age, CCI, and stroke risk can help plan targeted 
  
approaches and interventions to improve adherence. Our results can help healthcare 
providers and managed care organizations to recognize the importance of adherence to 
NOAC medications among patients to prevent clinical risks including stroke, DVTPE and 
bleeding events. The study provides a valuable estimate of the economic burden in AF 
patients using NOACs and warfarin. These cost estimates can be further used as inputs in 
the studies involving cost-effectiveness analysis and indirect treatment comparisons. We 
found the higher drug costs for NOACs were offset by lower inpatient costs, outpatient 
costs, and HCRU; which can lead to overall monetary savings to the patient taking 
NOACs and to the healthcare system. Overall, the conducted research provides 
comprehensive evidence to help support NOACs as an optimal treatment choice for the 
AF patients.  
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PREFACE 
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AND RIVAROXABAN) 
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ABSTRACT 
Introduction: The prevalence of atrial fibrillation (AF) in the United States (US) is 2.7 
to 6.1 million and is a leading cause of stroke (fivefold risk in AF patients).  Novel Oral 
Anti-coagulants (NOACs including Dabigatran and Rivaroxaban) are new promising 
drugs with better or similar efficacy to lower stroke risk and fewer side effects compared 
to warfarin in the clinical trials. Adherence to the medication therapy is crucial in 
improving efficacy, reducing the costs and hospitalizations. Since the therapy is relatively 
new, very few studies have examined the medication adherence to NOACs and its pattern 
over time. This observational study captured the medication adherence and its trend in the 
NOAC users vs. warfarin users using Proportion of Days Covered (PDC) over a period of 
12 months in a real-world setting.  Furthermore, the study examined short and long-term 
factors associated with medication adherence to NOACs. 
Method: A retrospective cohort study was conducted utilizing data from the Optum® 
Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) database between January 
1, 2010, and December 31, 2012. The study population was identified based on 
documentation of ≥ 1 diagnosis of atrial fibrillation or flutter ICD-9 code 427.31/32, age 
≥18 years and CHA2DS2VASC score ≥1.  Adherence was calculated using PDC as (Total 
Number of days covered by NOAC drugs as a class/ Number of days between index 
prescription date to the end of the calendar year, disenrollment, or death) for 3, 6, 9 and 12 
months.  The patient was defined as ‘adherent’ if PDC was ≥80%.  Predictors of 
adherence (1= PDC ≥80%, 0=<80%) were evaluated at 6 and 12 months using the 
logistic regression model controlling for age, gender, insurance type, pre-index cardiac 
drug use (beta-blocker, Angiotensin-II receptor blocker [ARB] or Angiotensin-converting 
 3 
 
enzyme [ACE] inhibitor, statin), CHA2DS2VASC score and Charlson’s Comorbidity 
Index (CCI). 
Results: A total of 5057 (N=1770 NOAC vs. N=3287 warfarin) patients with a mean age 
of 66 years were included in the cohort based on the inclusion and exclusion criteria.  For 
a 12-month follow-up, the proportion of adherent (PDC ≥80%) patients were higher 
among NOACs users (78.42%) compared to warfarin users (61.88%). Similarly, the 
patients using NOACs were consistently more adherent than warfarin users for 3, 6, 9 and 
12 months of adherence assessment. The proportion of adherence among NOAC users 
was high at 3-months assessment (84.30%) and declined over time [6 months (82.80%), 9 
months (76.45%)]. A similar pattern of decrease in adherence over time was observed for 
warfarin users.  Using multivariate logistic model controlling for the confounders; Age 
(OR=1.030, 95% CI 1.015-1.045), a CCI score of < 2 (OR= 1.460, 95% CI 1.108-1.923), 
and statin use were positively associated (p≤ 0.05) with an increase in medication 
adherence for 12 months among NOAC users. For short term NOAC use (6 months), 
patients with low-risk (based on the CHA2DS2VASC score of 1,2) were 27% less likely 
to adhere to the NOAC treatment (OR = 0.725 95% CI 0.580-0.907) compared to the 
high-risk patients (CHA2DS2VASC score of ≥3).   
Conclusion: Overall, patients taking NOACs have better (short and long-term) adherence 
to the therapy compared to warfarin users. Age, CCI and statin use were major predictors 
of both short and long-term adherence to NOACs.  The CHA2DS2VASC score 
significantly associated with short-term adherence while statin use was specifically 
associated with long-term adherence to NOACs. The results obtained from the study will 
help clinicians and healthcare providers to understand the use of these (especially 
 4 
 
NOACs) drugs in a real-world setting and help implement therapy in practice to provide 
optimal benefits to the patients. Further research on subgroups and their treatment 
patterns (including switching) is warranted. 
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BACKGROUND 
Atrial Fibrillation and Prevalence 
Atrial Fibrillation (AF) is a common condition causing cardiac rhythm disturbance due to 
structural or electro-physical abnormality resulting in abnormal impulse formation.1  In 
2010, the prevalence of AF in the United States (US) was 2.7 to 6.1 million and is 
expected to grow between 5.6 and 12 million in 2050.2,3   Approximately 70% of patients 
with AF are of the age between 65-85 years.4   AF can be caused by ischemic heart 
disease, heart failure, hypertension while other causes of AF may include 
hyperthyroidism, acute infection, alcohol withdrawal, or post-surgery.  The symptoms 
manifested in AF may include palpitation, dizziness, sweating, and shortness of breath.5  
AF is one of the key risk factors for ischemic stroke, increasing the risk up to 5-fold and 
accounts for one-third of all hospitalizations in the US for cardiac rhythm disturbances.6   
Treatment of Atrial Fibrillation 
Treatment options for AF primarily include antiplatelet, anticoagulant, beta blockers, 
calcium channel blockers, sodium and potassium channel blockers.7  Anticoagulants 
significantly decrease symptoms and health outcomes in AF leading to greater benefits.8  
Anticoagulants prevent blood clots and are used to treat existing blood clots.  
        Anticoagulants and their use in AF 
Warfarin is an oral vitamin K-antagonist approved in 1954 and has been a gold standard 
of care for more than 50 years.  It acts on multiple sites in the clotting cascade by 
preventing the synthesis of main coagulation factors, including II, IX, VII, and X by 
inhibiting vitamin K-dependent γ-carboxylation to work as an anticoagulant.9  Warfarin 
as an anticoagulant has shown to reduce the risk of stroke, myocardial infarction, and 
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death.  In a randomized clinical trial (RCT) of 973 patients aged 75 years or over in the 
United Kingdom (UK), the risk of hemorrhage was significantly (p≤0.05) lower for 
warfarin (1.4%) compared to aspirin (1.6%) 10,11.    
The variable dosing, frequent dose adjustments and narrow window for therapeutic use in 
warfarin have prevented it’s the widespread use in patients. Moreover, drug-interactions 
with concomitant medications, change in the diet, and the need for periodic monitoring 
has made warfarin use challenging for clinicians and patients. Due to these restrictions, 
many AF patients cannot use warfarin.12  In some patients, warfarin cannot be 
administered due to other factors such as non-response, poor adherence, unwanted side-
effects, etc.  The unmet need can be fulfilled using Novel Oral Anticoagulants (NOACs) 
which have recently proven to exhibit better efficacy, safety, and convenience compared 
to the existing warfarin treatment.  
Novel Oral Anti-Coagulants (NOACs)  
NOACs include two newly approved oral drugs, dabigatran “Pradaxa” (2010) and 
rivaroxaban “Xarelto” (2011). Dabigatran was the first oral anticoagulant approved in the 
US by the Food and Drug Administration (FDA) in 50 years.  It acts as a thrombin 
inhibitor and is indicated for reducing the risk of stroke, systemic embolism, treatment of 
deep venous thrombosis (DVT) and pulmonary embolism (PE) in AF patients.  In an 
RCT involving 18,113 patients with a primary outcome being the stroke (of any type), the 
risk of hemorrhagic strokes with dabigatran was also significantly (74%) lower than that 
of warfarin.13  Dabigatran is given as a fixed dose of 110 or 150 mg twice daily, and 
requires negligible monitoring and has a peak effect in 1-2 hours as opposed to 4-5 days 
in warfarin.14   
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Rivaroxaban was the first oral factor Xa inhibitor approved by the FDA.  In ROCKET-
AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with 
Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation) with 14,264 patients, rivaroxaban was non-inferior to warfarin in annual 
rates of stroke and systemic embolism (1.7% versus 2.2%) 15.    Similar to dabigatran, 
rivaroxaban has a rapid onset of action, requires twice daily dosing and has lower side 
effects compared to warfarin. Apaxiban and edoxaban, both factor Xa inhibitors were 
approved in December 2012, and January 2015 respectively.  Based on the data 
availability for our study (2010 to 2012 only), apaxiban and edoxaban will not be 
included as a part of the hypothesized research plan.   
Overall, NOACs have shown better or similar efficacy compared to warfarin in the 
clinical trials.  Few benefits of NOACs include quick time-to-peak effects, fewer drug to 
drug and dietary interactions, fixed dosing regimens, and requires little monitoring.  Now 
the reversal antidotes for NOACs (idarucizumab, andexanet alfa) are available. 
Disadvantages of NOACs include an inability to administer to patients with a prosthetic 
heart valve or stage V chronic kidney disease.12  
Adherence and NOACs 
Adherence has been defined as “An active, voluntary, and collaborative involvement of 
the patient in a mutually acceptable course of behavior to produce a therapeutic 
result”.16,17 Osterberg categorized measurement of adherence into indirect (pill count, 
prescription count, Medication Event Monitoring Systems [MEMS] cap, questionnaires) 
and direct method (directly observed therapy, metabolite in blood, and biological marker 
in the blood)17.   
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Since their (NOACs) launch in 2010-2011, there has been limited literature published on 
“real-world adherence to the NOACs” using large observational studies.  For oral 
anticoagulants based on the “Randomized Evaluation of Long-term Anticoagulant 
Therapy” (RELY) trial, the discontinuation rates at 1 year (using pill count) for 
dabigatran, and warfarin were 15.5%, and 10.2%, respectively.  In the ROCKET AF trial, 
discontinuation rates were similar between rivaroxaban and warfarin groups (15.7% vs. 
15.2%).  Although it is essential to acknowledge that trial data has some limitations as the 
adherence reported in the trials is calculated in a controlled environment.   
Study Rationale and Justification 
A small number of studies have reported adherence using different methods (MPR, PDC, 
Persistence gap of 60 to 180 days) for NOACs.18-22  Although the clinical guidelines 
recommend the use of NOACs for anticoagulation, the utilization of dabigatran and 
rivaroxaban remains sub-optimal in the real-world. Adherence to the medication therapy 
is crucial in improving the efficacy, reducing the costs and hospitalizations. Since the 
NOAC therapy is relatively new, it is not yet widely accepted and prescribed as warfarin 
by clinicians and healthcare providers. 
Not many studies have examined the medication adherence of NOACs and its patterns 
over time.  This observational study captured medication adherence (NOACs vs. 
warfarin) and its trend using Proportion of Days Covered (PDC) over a period of 12 
months in a real-world setting.  Furthermore, short and long term predictors of adherence 
to NOAC therapy were evaluated.  The results obtained from the study will help 
clinicians and healthcare providers to understand the use of these drugs in a real-world 
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setting and help make a suitable therapeutic choice in practice to provide optimal benefits 
to the patients. 
Hypothesis: Ho = There is no statistical difference in estimate of medication adherence 
between AF patients taking NOACs and warfarin.  
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METHODOLOGY 
Study Design 
This was a retrospective cohort study to compare adherence between NOAC and warfarin 
users and examine its patterns over a one-year period.  
The study was conducted using commercial insurance de-identified claims data from 
January 1, 2010, to December 31, 2012, using a large-scale US managed care health plan 
affiliated to Optum® Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) 
database. The primary outcome of the study was adherence calculated using PDC at 3, 6, 
9 and 12 months and assessment of predictors of adherence at 6 and 12 months.  
Data Source: The database mainly includes medical claims and pharmacy claims data.  It 
contains details on dates of service, place of service, International Classification of 
Diseases, Ninth Revision, (ICD-9) diagnosis codes, provider type, National Drug Code 
(NDC), drug quantity dispensed, days supplied, charges, deductibles, and copayments.  
The large US health plan database includes 14 million patients and 500,000 Medicare 
enrollees.  The member file constitutes the demographic data and eligibility information.  
The database also includes a drug file, a medical file (outpatient), standard pricing file 
(cost) and a confinement file for inpatient data. The database comprehensively covers 
diverse geographical areas of the US.  All study data were accessed using Health 
Insurance Portability and Accountability Act (1996) compliant protocols.  To ensure the 
patient confidentiality, no identifiable protected health information was used or analyzed 
during the study.23  The data was accessed using the server at the University of Rhode 
Island (URI) and analyzed using SAS EG 7.1.   The study was also approved by an 
Institutional review board at URI. 
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Sampling design/procedures:  All patients between January 1, 2010, to December 31, 
2012, were identified.  Patients with warfarin, dabigatran or rivaroxaban (NOACs) were 
identified using the NDC codes and brand name using REDBOOK. The index date was 
defined as the date of first prescription fill of the NOAC or warfarin in their respective 
drug cohort. Patients with at least two claims for the study drugs in the post-index period 
were included. Patients were included based on at least one AF or atrial flutter diagnosis 
claim identified using the medical file (inpatient or outpatient) with an ICD-9 code of 
427.31/427.32 during the pre-index period or 30 days within the index date. In addition to 
the AF patients, subjects with atrial flutter were also included since a large proportion of 
patients with atrial flutter also suffer from atrial fibrillation (overlap) and the 
recommended treatment is similar for AF and flutter for the prevention of stroke. Patients 
with age ≥ 18 years were included. Patients with concomitant use of warfarin and NOAC 
during the post-index assessment period were excluded. Few patients previously used 
warfarin in the pre-index period prior to starting the NOACs. Since, NOACs are also 
prescribed to fulfill the unmet need in few patients with prior warfarin use, to avoid 
exclusion of any NOAC user (and sample size considerations), the inclusion of these 
patients was based on the definition of “warfarin naïve.” Based on the definition of 
‘warfarin naïve’ in RELY trials, a patient was defined ‘warfarin naïve’ if there was no 
use of warfarin 2 months before the index date (first fill) of the NOAC or if the NOAC 
was used for a duration of at least 5 or more months.24   This criterion was to ensure that 
we capture all NOAC users and avoid any potential bias in regards to prior warfarin 
therapy for assessment of outcomes.  For sensitivity analysis, we also examined no use of 
warfarin 100 days before the index date as a threshold.  Thus, the index date of these 
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“warfarin naïve” users was based on the first prescription fill of NOACs.  Data based on 
RELY trials showed no heterogeneity between patients who had prior warfarin use (based 
on the above definition) and those with no prior warfarin therapy. Age was used as a 
continuous variable.  Furthermore, patients with CHA2DS2VASC score ≥1 (1-9) were 
identified using ICD-9 codes. CHA2DS2VASC characterizes the risk of stroke based on a 
score composed of (congestive heart failure, hypertension, age >75 years, diabetes, prior 
stroke, pulmonary or vascular disease, age [65-74 years], sex [as female]) (Please refer to 
Appendix Table 1 for ICD-9 codes and variable categorization). The patients with at least 
6 months of pre and post index continuous eligibility with a permissible gap of 45 days 
were included in the cohort.  Patients with hyperthyroidism (ICD-9 242.9) were excluded 
from the patient cohort since it may be the probable cause of AF but is not related to 
cardiac pathways.  
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Figure 1.1: Study design and timeline 
 
 
 
 
 
 
 
 
 
 
Measurement of Adherence  
The medication possession ratio (MPR) and PDC are the most frequently used measures 
to estimate adherence. The denominator in MPR is defined based on the difference 
between first and the last fill and doesn’t account for discontinuation of the drug. 
Furthermore, overestimation of MPR might occur due to early refill and if patients take 
concurrent medications of the same class. PDC is the most favored method to measure 
adherence in the recent years since it accounts for non-persistence where the denominator 
is days between first fill and end of the study.25 
Definition of Outcome  
Adherence was calculated using PDC as follows =   
Numerator: Number of days covered by NOAC drugs as a class (using fill date and 
supply days); at least 2 fills were required to calculate the PDC. The days were truncated 
if days of supply went beyond the study period.  “The PDC calculation also considered 
when patient refilled their medication before exhausting the previous fill by adjusting the 
12 months
Post-index period for evaluation of adherence
Index date 
Date of first fill 
for study drug
Continuous Enrollment
12/2012 or 
end of 
continuous 
enrollment
1/2010 or 
start of 
continuous 
enrollment
Follow-up period (≥12 months)
9 months
6 months
3months
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prescription start date to be the day after the previous fill ends”.26 The fills beyond the 
study period were truncated. 
Denominator: Number of days between index prescription date to the end of the calendar 
year, disenrollment, or death.    
                                                     Proportion of Days Covered 
                           End of study date – first prescription fill date 
For calculation of PDC, patient’s measurement period was defined as the index prescription 
date to the end of the assessment period, disenrollment, or death. 
Data Analysis:  
Adherence was presented for NOACs users and warfarin users as PDC ranging from 0-
100%.  PDC above 100 was truncated to 100% (e.g., If a patient has a PDC of 110%, the 
patient was still considered as 100%. No patient was excluded based on the PDC 
truncation).27  Categorical analysis was performed to present frequency and percentage of 
patients with adherence (PDC) ≥80% across the 2 groups (NOACs users vs. warfarin 
users).  Adherence was assessed at 3, 6, 9, 12 months of use.  
Secondly, the descriptive characteristics were analyzed and compared across adherent 
and non-adherent cohorts using NOAC therapy.   
Finally, multivariate logistic regression was performed to investigate the predictors of 
adherence among NOAC patients (Y = α+β1X1 + β2X2 + β3X3 + …………+ βiXi + €).  
Adherence using PDC (dependent variable) ≥80% and < 80% was coded as 1 and 0 
respectively. Demographic variables, including, gender, age (continuous variable), 
region, Charlson’s Comorbidity Index (CCI 0, 1-2, >2 based on parametric assessment), 
CHA2DS2VASC score (1-2 as low-risk, >2 as high-risk groups)28 were used as covariates. 
Pre-index cardiac medications were selected based on American Heart Association 
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(AHA) medication classes recommended for AF therapy. Furthermore, these drug classes 
(beta-blockers, Angiotensin-II Receptor Blocker [ARB] or Angiotensin-converting 
enzyme [ACE] inhibitors, and statins) were as covariates in the pivotal dabigatran trial.  
The type of insurance was also evaluated as possible confounders.  First, the adherence 
(DV) was tested separately against each covariate using bivariate analysis. Univariate 
logistic regression was performed for the continuous variables and association with 
categorical variables was tested using a chi-square test.  Possible confounders were 
identified, and their association with adherence was examined (with p-value ≤0.25).  Due 
to the clinical significance, CHA2DS2VASC score was considered as a major confounder 
and was retained in the final model.   
Next using the basic model, the multicollinearity between the variables of interest was 
tested to check whether the regressor variables are similar (in direct linearity) to other 
regressor variables.  The collinearity was examined using the condition number (if >30 
then collinearity exists) and the proportion of variance statistics for the eigenvalues. The 
multicollinearity was tested by examining the Variance Inflation Factor (VIF) for the 
variables. A VIF > 5 indicates collinearity among variables. Only one of the two or more 
collinear variables was selected for inclusion in the final multivariate model.   
Moreover, the predictive model was primarily built using 2 methods 1. Automatic 
backward elimination process and 2. Manual Elimination process for sensitivity analysis.  
Using the automatic backward elimination process, the model with the preliminary set of 
variables was refined by sequentially removing variables which do not contribute to the 
model.  It was performed as an iterative process to predict adherence by examining Wald 
p-values, with confirmation through likelihood ratio testing (p-value > 0.05 confirming 
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exclusion). This backward elimination process was repeated until a basic model was 
obtained.  Similar to backward elimination, variables were manually evaluated by 
elimination of the non-significant variable based on Wald p-values.  Once eliminated, the 
model was iteratively re-ran with the remaining variables and the process was continued 
until a parsimonious model with only significant covariates was obtained. 
Furthermore, all two-way interactions between CHA2DS2VASC and other independent 
variables were also investigated for possible synergistic relationships.  Significant 
interaction terms were retained. As a part of sensitivity testing, the model with 
independent variables + interaction term of CHA2DS2VASC score with each independent 
variable (one at a time) was examined. Comparison of models was also performed using 
Akaike Inclusion Criteria (AIC – lower is better).  Moreover, the goodness of fit of the 
models was examined by Hosmer-Lemeshow test.29  If p-value ≥ 0.05, the model fit is 
good. Model fit statistics were evaluated examining -2 log-likelihood estimate.  Larger -
2log-likelihood estimate indicated a poorly fitted model.   
Results from the final parsimonious model were presented with the help of adjusted odds 
ratios along with their 95% CI, and p-values obtained from two-sided tests with a 
significance level of p-value ≤0.05.  
For sensitivity analysis, predictors of short-term adherence (at 6-month assessment) to 
NOACs were also investigated.  
 
RESULTS 
We found a total of 25,120 users of NOACs and 149,359 users of warfarin within the 
study period. A total of 14,618 NOAC and 120,607 warfarin users had 2 or more 
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prescription fills. Out of 14618 NOAC patients, 4332 patients had a prior warfarin use in 
the pre-index period, and the definition of ‘warfarin naïve’ was used to screen the 
patients. Based on the definition of ‘warfarin naïve’, 1107 out of 4332 patients were 
included as NOACs. The sensitivity analysis using a threshold of 100 days instead of 60 
days led to a very minor change in the sample size and hence threshold of 60 days was 
retained and used. A total of 1032 patients were excluded due to an overlap (concomitant 
use of warfarin and NOACs) in the post-index period.  Based on the other inclusion 
criteria (diagnosis of atrial fibrillation in pre-index period or 30 days within the index 
date, ≥18 years, continuous enrollment for 6 months pre and post-index, and 
CHA2DS2VASc ≥1), a total number of warfarin and NOAC patients were 8130 and 4758 
respectively. Based on 6 months of drug use a total number of 3,453 NOAC users and 
5596 warfarin users were included in the analysis.  At 12 months of the assessment 
period (drug use), the study sample consisted of 5057 patients. A total of 1770 NOAC 
patients and 3287 warfarin patients met the inclusion and exclusion criteria and were 
included in the final analysis cohort. Figure 1.1 in Tables and Figures describes the 
cohort sample selection in detail. 
Baseline Characteristics among NOAC and Warfarin patients  
Based on the study sample of 5057 patients, the mean age of the sample was 66 years 
with more men (66.7%) than females. Most of the patients were either from the South or 
the Midwest (65%). Most of the patients (65%) were categorized as moderate to high-risk 
of stroke based on CHA2DS2VASC score >2. Over 80% of patients in the cohort had CCI 
above 0. For medication use, statins were the most frequently used drugs (50% of 
patients) followed by beta-blockers used by more than 25% of the sample.   
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Based on the chi-square test, most of the patient characteristics were different across the 
NOACs and warfarin. More than 50% of NOAC users were from the South (vs. 37% for 
warfarin users). For the stroke risk based on the CHA2DS2VASC score, a higher 
proportion of warfarin users had a moderate-high risk (more severe) compared to NOAC 
users (67% vs. 60%).  Most of the patients had CCI score > 1(85%) where patients on 
warfarin therapy were slightly severe (with a higher proportion of 3+ comorbidities) 
compared to the NOAC users (48% vs. 34%). The use of statins was high in both cohorts 
(>50% of the patients).  Please refer to Table 1.1 in Tables and Figures.  
Adherence measured by PDC 
Adherence was measured at 3, 6, 9 and 12 months post the index date. Overall, 
NOAC patients had a higher adherence (PDC ≥80%) to the treatment as compared to the 
warfarin therapy.  At 12 months of follow-up, the proportion of adherent patients using 
NOAC was 78.42% (N=1388/1770) compared to 61.88% (N=2034/3287) for warfarin 
patients. The trend for higher adherence in NOACs vs. warfarin was preserved for 3, 6, 9-
month assessment period. Table 1.2 in Tables and Figures I compare the adherence 
measured at different time points between NOAC and warfarin cohorts. The proportion 
of adherence among NOAC patients at 3 months was (N=2859/3453) 84.30% and 
declined over time (82.80% for 6 months and 76.45% 9 months).  Similarly, the 
proportion of adherence among warfarin users at 3 months was 77.43% (N=5224/6747) 
followed by 72.61% and 61.88% for at 6 and 9 months respectively. 
 
Baseline Characteristics among Adherent and Non-Adherent NOAC patients 
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          For the cohort based on the drug usage for 12 months, the patient demographic and 
clinical characteristics were summarized for adherent vs. non-adherent NOAC users at 
baseline (index date).  Age, CHA2DS2VASC score, type of insurance, and use of statins 
were significantly (p≤0.05) different across the adherent and non-adherent patients. The 
mean age of patients was 65 years with adherent (66 years) patients being older than the 
non-adherent (62 years) patients. The cohorts consisted of more men (69.3%) than 
women (30.7%). The majority of patients were from the South (51.3%) or the Midwest 
(21.9%), and more than 60% of the final cohort received point-of-service (POS) 
insurance.  
There were 39.4% patients with a CHA2DS2VASC score of 1-2 (low risk) and 38.8% 
with a CHA2DS2VASC score > 2 (termed as a moderate-high risk of stroke). Patients 
with moderate-high risk of stroke (based on the CHA2DS2VASC score) were more 
adherent to medications compared to the low-risk patients. The CCI scores were well 
distributed across adherent and non-adherent patients. In regards to the cardiac 
medication use, statins and beta-blocker use were higher among adherent patients 
compared to the non-adherent patients. Table 1.3 in Tables and Figures I describes the 
patient demographic and clinical characteristics in detail among adherent and non-
adherent NOAC patients. 
Bivariate Analysis  
The bivariate analysis between adherence and independent variables was initially 
performed to select the variables needed in the multivariable model. Variables with an 
association and a cut-off threshold of p ≤ 0.25 were included for further analysis.  Age, 
insurance type, region, CHA2DS2VASC score, statin and beta-blocker use was associated 
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with the adherence to the therapy. Table 1.4 in Tables and Figures I describes the 
significance estimates for the bivariate analysis. 
Prior to building the multivariate model, multicollinearity was examined using the 
eigenvalues (<10), conditional index (<35) and Variance Inflation Factor (<3).  
Multivariate analysis  
A multivariate logistic regression was modeled to examine the predictors of adherence 
for 12-month assessment in NOAC patients. The dependent variable was adherence (1,0), 
and age, CHA2DS2VASC score, Charlson’s comorbidity index (CCI), region, insurance 
type, statin use, beta blocker use was selected as covariates based on the bivariate 
analysis. CHA2DS2VASC Score, Charlson’s comorbidity index were included 
irrespective of association (in the bivariate analysis) due to their clinical significance. The 
parametric assessment was performed on the variables to assess the distributional 
characteristics.  The CHA2DS2VASC score was categorized as low risk (1-2) and 
moderate-high risk (>2). The CCI was also categorized as (0, 1-2 and ≥3). Based on the 
preliminary backward elimination model, age, CCI, insurance type, statin use and 
monthly drug cost were significantly associated.   
A final model consisted of all significant variables from the backward elimination model 
and CHA2DS2VASC score. The final model converged with an Akaike Inclusion Criteria 
(AIC) of 1800.21. Hosmer-Lemeshow (goodness of fit) was 0.5393 (p>0.05). The c-
statistic was 0.627. (Tables and Figures I – Table 1.4). 
Based on the final model, age (OR-1.030, 95% CI 1.015-1.045), a CCI score of < 2 (OR- 
1.460, 95% CI-1.108-1.923), and statin use were positively associated with an increase in 
medication adherence. (Table 1.4 in Tables and Figures I).  The final model was further 
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tested for diagnostics to examine the Pearson’s and chi-square residuals. The top 5 
outliers based on the Cook’s distance were removed, and the model was re-examined for 
any considerable change in the estimates and inference. Since the change was minor and 
did not significantly affect the model outputs, the 5 observations were added back to the 
final model.   
Although not statistically significant at 12 months, low-risk patients based on the 
CHA2DS2VASC score were less likely to be adherent to NOAC therapy compared to 
high-risk patients.  
Sensitivity analysis at 6 months 
Using the same model building procedure, predictors of adherence were examined for 
short-term NOAC use (6 months). At 6 months, age, CCI and statin use remained 
consistently significant as seen in multivariate analysis for 12 months. Additionally, it 
was found that CHA2DS2VASC score and region were significant predictors (p ≤ 0.05) of 
adherence to NOACs for short term use.  The patients with low risk (based on the 
CHA2DS2VASC score of 1,2) were 27% less likely to adhere to the treatment (OR-0.725 
95% CI 0.580-0.907).  Please refer to Table 1.5 Tables and Figures and Appendix I Table 
3 for the complete model. 
 
DISCUSSION 
Our analysis found higher adherence to NOAC therapy as compared to warfarin over a 1-
year period. This result was consistent over the short and long-term when examined at 3, 
6, 9 and 12-month interval. The adherence decreased over time in both the cohorts 
(NOAC vs. Warfarin).  
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Unadjusted estimates suggested age, insurance type, region, CHA2DS2VASC score, 
statin, and beta-blocker use was associated with the adherence to the therapy. For 
multivariate analysis controlling for the covariates, an increase in age, fewer co-
morbidities, and statin use led to better adherence whereas low-risk CHA2DS2VASC led 
to lower adherence. It was interesting to know that CHA2DS2VASC score and region was 
significantly associated with short-term adherence to NOACs, but not long-term, whereas 
statin use was not influential predicting adherence based on both short and long term use.  
Our study was the first to examine the patterns of short and long-term NOAC use and 
assess predictors of adherence among a large nationwide database in a real-world setting.  
Many observational studies have shown an estimate of adherence to NOAC therapy is 
variable ranging from 40-88%.30,31  However, the assessment of adherence has been done 
in different settings, including clinics, self-reported, public claims database, commercial 
claims databases including IMS, MarketScan, Humana, etc. with varying assessment 
period (2010-2014).30,32-34 The estimate of adherence to NOACs found in our study 
(78.4%) is consistent with other database studies. Similar studies have attempted to 
understand the adherence of NOACs over a period of 3, 6, 12 and 24 months, and have 
shown higher adherence of PDC ≥ 80% (approximately 75%) for assessment shorter time 
intervals of 3 months after the index date and the adherence decreased over time (63% for 
12 months).32  
In an observational study of Veteran Affairs (VA) cohort of 5,376 patients with AF 
initiated on dabigatran, 72% of patients had the proportion of days covered (PDC) ≥ 80%.  
Moreover, the mean PDC reported was 84% ± 22%.34  In another retrospective study 
evaluating electronic medical and pharmacy records within the University of California 
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(UC) Davis Medical Center with 400 patients, the mean MPR for patients using 
dabigatran was 0.63.  Overall, 43% of the patients taking dabigatran had an MPR of < 
0.80. The study found gender (female), and PRN (prescription as necessary) medication 
use as predictors of low adherence among patients.18  In another nationwide observational 
study in Denmark with 2960 patients, 1-year PDC for dabigatran was 84%.19  The PDC 
for rivaroxaban and dabigatran using Healthcare claims from the Humana database 
between July 2013 and December 2014 was >65%.33  Another study using IMS Health’s 
LifeLink Health Plan Claims Database from 2010 to 2012 found mean MPR as 0.73 and 
40% patients with adherence above ≥ 0.80.30 
In a study using US Department of Defense administrative claims data, the persistence 
rate (with a gap defined by ≥ 60-day discontinuation) for dabigatran versus warfarin was 
72% versus 53% for 6 months and 63% versus 39% for 1 year respectively.20  In a 
German study of 1204 patients, discontinuation rates of rivaroxaban in daily care for 
stroke prevention in atrial fibrillation (SPAF) patients were approximately 15% in the 
first year and very low thereafter.22  Furthermore, persistence (no gap of => 60 days) was 
compared between rivaroxaban and warfarin in a US based study using MarketScan data 
(2010-2013).  Patients were more persistent to rivaroxaban (77%) as compared to 
warfarin (58%).35   
Our study found higher age, the risk of stroke (CHA2DS2VASC score >2), statin use, and 
lower CCI scores as major predictors of adherence consistent with the previous 
literature.20,22,36,37  Younger age, male as a gender, low stroke-risk, poverty, higher 
education and poor cognitive function, have also been found to be associated with lower 
adherence.  Another recent study based on the Danish patient registry reported an overall 
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1-year PDC equal to 83.9 % and found that females (OR-1.06), patients using 
cardiovascular drugs and CHA2DS2VASC ≥2 (OR-1.12) were major predictors of 
adherence among dabigatran users.19 
Numerous studies have reported discontinuation of NOACs is primarily due to bleeding-
related side effects.  In a study on 467 Chinese patients in a clinic, dyspepsia was the 
most common cause of discontinuation, followed by adverse events and bleeding events 
including gastrointestinal bleeding and intracranial hemorrhage.  Furthermore, dosing 
frequency, lack of laboratory monitoring, fear of side effects, and cost were other minor 
causes of discontinuation of therapy.38 In addition to understanding the relative impact of 
anticoagulants-associated complications (such as bleeding), future research should 
emphasize on creating greater awareness and partnership between patient and physician 
for better decision making around anticoagulation.39 
The OPTUM database is a large nationwide database and provided sufficient sample size 
to interpret results robustly. However, claims data can lead to selection bias due to 
imprecise billing codes.  Moreover, it should be acknowledged that OPTUM is mostly a 
commercial database under-represented by the elderly population (above 65 years). Over 
65% the sample was represented by males, predominantly from the South or the Midwest 
and the database lacked information in regards to the race, ethnicity, and reason for 
discontinuation of therapy.  
Although the clinical variables (e.g. INR values, ventricular ejection fraction, body mass 
index) were not included in the dataset, clinical determinants such as CHA2DS2VASC 
and CCI helped to control for disease severity by considering hypertension, prior 
cardiovascular disease, diabetes and other co-morbidities. The claims data lacks 
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information regarding reasons for discontinuation or side-effects due to the drug which 
might help explain non-adherence estimates. Furthermore, adherence assessment based 
on 3, 6, 9, and 12-month windows might lead to truncation of the data. Therefore, the 
adherence assessment windows were kept close at every 3 months.  It is also important to 
understand that the dosing of warfarin is variable and frequently adjusted. We also looked 
at the distribution of days of supply to explore a potential bias. The distribution of the 
days of supply for warfarin and NOACs was primarily around 30 and 60-day dosing 
which substantiated that the therapies might be comparable.  Prior use of cardiac drugs 
was also accounted, and selection of the drugs was based on AF therapy recommended 
by American Heart Association (AHA).40 These drugs were also used as covariates to 
understand the individual effects in the dabigatran pivotal trials. However, aspirin use 
was not comprehensively captured in the claims database due to its availability as over 
the counter (OTC) drug. The differences in the descriptive characteristics might be 
explained by the fact that NOACs might be prescribed to patients who have unmet need 
after warfarin therapy, this might lead to potential channeling or selection bias, in our 
study we did not control the selection bias using propensity scores. 
Sensitivity analysis helped to confirm the results over a short and long-term period. To 
eliminate the bias in regards to variable follow-up time, adherence was assessed for 
patients who had medication use at regular intervals up to 3, 6, 9, and 12 months.  
 
CONCLUSION     
Overall adherence to NOACs is suboptimal and decreases over time. Patients taking 
NOACs have higher (short and long-term) adherence to the therapy compared to warfarin 
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users. Age, CCI, and statin use were major predictors of both short and long-term 
adherence while CHA2DS2VASC score was associated with short-term adherence but not 
with long-term adherence.  The short and long-term estimates of adherence to NOACs 
and associations observed in our study may help the healthcare providers and managed 
care organizations to strategize and provide optimal care to the patients by improving 
adherence to reduce clinical complications, healthcare resource use, and costs. Further 
research on individual drugs using matched cohorts and their treatment patterns 
(including switching) is warranted. 
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TABLES AND FIGURES I 
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Figure 1.2: Cohort Selection based on Inclusion and Exclusion Criteria  
 
Patients with ≥2 fills in post index period 
NOAC = (N=14618) and Warfarin (N=120607)  
Adult patients Age ≥ 18  
NOAC (N=10345) and Warfarin (N=114230) 
 
Continuous enrollment for 6 months’ pre-index and 6 months’ post 
index (45 Day gap)   
Warfarin (N=29269), NOAC (N=5790) 
 
NOAC  
3 Months Drug Use (N=4070) 
6 Months Drug Use (N=3453) 
9 Months Drug Use (N=2539) 
12 Months Drug Use (N=1770) 
 
Warfarin  
3 Months Drug Use (N=6747) 
6 Months Drug Use (N=5596) 
9 Months Drug Use (N=4326) 
12 Months Drug Use (N=3287) 
Exclude Patients with ≤1fills  
Adult patients with any NOAC Drug Use (N=25,120) 
Warfarin N = (149395) 
1. if warfarin is used before 
NOAC: if a patient has warfarin 
prescription < 60 days or gap 
between warfarin and NOAC is 
5 months or greater; then the 
patient is termed as warfarin 
naive 
2. if warfarin use with or after 
NOAC; then patient is 
excluded (out of 14618 NOAC 
patients, 4332 where warfarin 
was used prior to NOAC in the 
pre-index period and the 
definition of warfarin naïve was 
used. Based on warfarin naïve 
definition 1107 patients were 
included as NOACs, 1032 were 
excluded due to overlap in the 
post index period) 
Diagnosis of Atrial Fibrillation (427.31) or Flutter (427.32) in pre-index or 
within 30days of index date; Warfarin (N=8834) NOAC (N=5164) 
CHA2DS2VASc ≥ 1;  
Warfarin (N=8130) NOAC (N=4758) 
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Table 1.1 Patient Demographic and Clinical Characteristic of NOAC vs Warfarin patients at 12-month assessment 
period 
Variable Description 
Statistic 
Response 
Category 
Total 
 (N= 5,057) 
NOACs  
(N= 1,770) 
Warfarin 
 (N= 3,287) 
P-value 
(Chi-sq) 
Age at index date  N 5057 1,770 3,287 <0.001 
 Mean (SD) 65.94 (11.61) 65.2 (10.56) 66.34 (12.13)  
 Median(IQR) 64 (58-75) 64 (59,73) 65 (58,76)  
 Range 18-86 26,86 18,86  
Gender Female 1,718 (33.97) 544 (30.73) 1,174 (35.72) 0.0004 
 Male 3,339 (66.03) 1,226 (69.27) 2,113 (64.28)  
Insurance type EPO 512 (10.12) 204 (11.53) 308 (9.37)  
 HMO 312 (6.17) 103 (5.82) 209 (6.36)  
 IND 1,030 (20.37) 280 (15.82) 750 (22.82)  
 Others 7 (0.14) 0 (0.00) 7 (0.21)  
 POS 2,945 (58.24) 1,104 (62.37) 1,841 (56.01)  
 PPO 251 (4.96) 79 (4.46) 172 (5.23)  
Region Midwest 1,469 (29.05) 388 (21.92) 1,081 (32.89) <0.001 
 Northeast 534 (10.56) 168 (9.49) 366 (11.13)  
 South 2,134 (42.20) 908 (51.30) 1,226 (37.30)  
 West 920 (18.19) 306 (17.29) 614 (18.68)  
Stroke risk (CHA2D2VASC) low risk 1,762 (34.84) 697 (39.38) 1,065 (32.40) <0.001 
 mod-high risk 3,295 (65.16) 1,073 (60.62) 2,222 (67.60)  
CCI category CCI score 0 715 (14.14) 311 (17.57) 404 (12.29) <0.001. 
 CCI score 1-2 2,140 (42.32) 851 (48.08) 1,289 (39.22)  
 CCI score 3 and+ 2,202 (43.54) 608 (34.35) 1,594 (48.49)  
Statin use Yes 2478(49.0) 917(51.81) 1561 (47.49) 0.003 
 No 2579 (51.0) 853 (48.19) 1726 (52.51)  
ACE ARB Inhibitor Yes 2382 (47.10) 874 (49.38) 1508 (45.88) 0.017 
 No 2675 (52.90) 896 (50.62) 1779 (54.12)  
Beta-blocker  Yes 1392 (27.53) 536(30.28) 856 (26.04) 0.001 
 No 3665 (72.47) 1234 (69.72) 2431(73.93)  
CCI- Charlson’s comorbidity Index, HMO – Health maintenance organization, PPO- Preferred provider 
organization, EPO -  Exclusive provider organizations, IND- Independent, POS-Point of service, ARB- 
Angiotensin Receptor Blocker, ACE- Angiotensin-converting enzyme 
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Table 1.2 Adherence Measured by PDC at Different Time-points 
Adherence  N Adherence  
NOACs 
N Adherence  
Warfarin 
p-value 
3 months 4070 3431 (84.30%) 6747 5224 (77.43%) <0.001 
6 months  3453 2859 (82.80%) 5596 4063 (72.61%) <0.001 
9 months 2539 1941 (76.45%) 4326 2677 (61.88%) <0.001 
12 months  1770 1388 (78.42%) 3287 2034 (61.88%) <0.001 
 
*PDC ≥ 80 = Adherent patient, Adherence measured by PDC at different time points  
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Table 1.3 Patient Demographic and Clinical Characteristics of Adherent Vs Non-adherent NOAC patients at 12-
month Assessment Period 
 
Variable Description 
Statistic 
Response 
Category 
Total 
(N= 1,770) 
Adherent 
 (N= 1,388) 
Non-Adherent 
 (N= 382) 
 
p-value 
Age at index date N 1770 1,388 382 <.0001 
 Mean (SD) 65.20 (10.55) 66.02 (10.16) 62.24 (11.42)  
 Median(IQR) 64 (59, 73) 64 (59,73) 62 (55,68)  
 Range 26,83 34,86 26,86  
Gender Female 544 (30.73) 426 (30.69) 118 (30.89) 0.9407 
 Male 1,226 (69.27) 962 (69.31) 264 (69.11)  
Insurance type EPO 204 (11.53) 143 (10.30) 61 (15.97) <0.001 
 HMO 103 (5.82) 73 (5.26) 30 (7.85)  
 IND 280 (15.82) 239 (17.22) 41 (10.73)  
 POS 1,104 (62.37) 862 (62.10) 242 (63.35)  
 PPO 79 (4.46) 71 (5.12) 8 (2.09)  
Region Midwest 388 (21.92) 317 (22.84) 71 (18.59) 0.0487 
 Northeast 168 (9.49) 132 (9.51) 36 (9.42)  
 South 908 (51.30) 689 (49.64) 219 (57.33)  
 West 306 (17.29) 250 (18.01) 56 (14.66)  
Stroke risk 
(CHA2D2VASC) 
Low risk 697 (39.38) 515 (37.10) 182 (47.64) 0.0002 
 Mod-high risk 1073 (60.62) 873 (62.90) 200 (54.36)  
CCI Category CCI score 0 311 (17.57) 239 (17.22) 72 (18.84) 0.5734 
 CCI score 1-2 851 (48.08) 676 (48.70) 175 (45.81)  
 CCI score 3 
and+ 
608 (34.35) 473 (34.08) 135 (35.34)  
Statin Use No 853 (48.19) 636 (45.82) 217 (56.81) 0.0001 
 Yes 917 (51.81) 752 (54.18) 165 (43.19)  
ACE ARB Inhibitor Use No 896 (50.62) 688 (49.57) 208 (54.45) 0.0910 
 Yes 874 (49.38) 700 (50.43) 174 (45.55)  
Beta-blocker Use No 1,234 (69.72) 980 (70.61) 254 (66.49) 0.1213 
 Yes 536 (30.28) 408 (29.39) 128 (33.51)  
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Variable Description 
Statistic 
Response 
Category 
Total 
(N= 1,770) 
Adherent 
 (N= 1,388) 
Non-Adherent 
 (N= 382) 
 
p-value 
CCI- Charlson’s comorbidity Index, HMO – Health maintenance organization, PPO- Preferred provider 
organization, EPO -  Exclusive provider organizations, IND- Independent, POS-Point of service, ARB- Angiotensin 
Receptor Blocker, ACE- Angiotensin-converting enzyme 
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Table 1.4 Logistic Regression Model to examine Predictors of Adherence in NOAC Patients at 12 Months 
 
Variables 
Odds 
ratios 
95% Wald 
Confidence Limits 
p-value 
Age 1.030 1.015 1.045 <.0001 
CCI -  CCI score 0   vs CCI score 3 and+ 1.275 0.879 1.850 0.2011 
CCI -  CCI score 1-2 vs CCI score 3 and+ 1.460 1.108 1.923 0.0072 
CHADS2VASC -  low risk vs mod-high risk 0.859 0.644 1.146 0.3010 
Insurance type -  EPO vs PPO 0.354 0.158 0.791 0.0114 
Insurance type -  HMO vs PPO 0.328 0.139 0.774 0.0109 
Insurance type -  IND vs PPO 0.517 0.229 1.170 0.1134 
Insurance type -  POS vs PPO 0.523 0.245 1.118 0.0946 
Statin use - No vs Yes 0.703 0.553 0.892 0.0038 
 
Note: Dependent Variable = Adherence (1,0), Independent Variables = Age, CHADS2VASC Score, 
Charlson’s Comorbidity Index, Insurance Type, Drug Use, Drug Cost (Statin Use, Ace Inhibitor Use, Beta 
Blocker Use, ARB Use) 
Interactions: All Independent variables with CHADS2VASC Score were tested and compared against a 
model without interaction. Final model selection was based on goodness of fit and AIC. 
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Table 1.5 Logistic Regression Model to examine Predictors of Adherence in NOAC Patients at 6 Months 
 
 
Effect 
Odds 
Ratio 
95% Wald 
Confidence Limits 
p-value 
Age 1.030 1.019 1.040 <.0001 
CCI Category - CCI score 0 vs CCI score 3 or + 3 1.448 1.080 1.942 0.0133 
CCI Category - CCI score 1-2 vs CCI score 3 or +3 1.276 1.026 1.587 0.0287 
CHA2D2VASC - low risk vs mod-high risk 0.725 0.580 0.907 0.0048 
Region -   Midwest   vs West 0.840 0.610 1.156 0.2838 
Region -  Northeast vs West 0.895 0.604 1.327 0.5812 
Region -  South vs West 0.694 0.524 0.919 0.0109 
Statin use - No vs Yes 0.763 0.633 0.918 0.0042 
 
Note: Dependent Variable = Adherence (1,0), Independent Variables = Age, CHADS2VASC Score, 
Charlson’s Comorbidity Index, Insurance Type, Drug Use, Drug Cost (Statin Use, Ace Inhibitor Use, Beta 
Blocker Use, ARB Use) 
Interactions: All Independent variables with CHADS2VASC Score were tested and compared against a 
model without interaction. Final model selection was based on goodness of fit and AIC. 
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APPENDICES I  
Appendix I:  Table 1 ICD-9 Diagnosis Codes 
 
  ICD-9 Codes  
AF Diagnosis  Atrial Fibrillation and Flutter 427.31, 427.32 
Hypothyroidism 240.9 
CHA2DS2VASC 
Score  
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.03, 404.11, 404.13, 404.91, 404.93, and 
428.x, 518.4 
Diabetes 250.x, 357.2, 362.0, and 366.41 
Hypertension 401.x, 402.x, 403.x, 404.x, and 405.x 
Stroke/ TIA 433,434, 435, 436 
 
Vascular disease 410,411,412, 413, 414, 443.8, 443.9 
 
Major Charlson’s 
Comorbidity Index 
diagnosis  
Myocardial Infarction 410, 412 
CHF 428 
Cerebrovascular disease  430-438 
COPD 490-496, 500-505, 506.4 
Paralysis  342, 344.1 
Chronic Renal failure 582, 585, 586, 588, 583.0 – 583.7 
Ulcers 531-534 
Cirrhodites 5712, 5714, 5715, 5716 
AIDs 042,044 
Metastatic tumor  196.0-199.1, 196.x 
Rothendler JA, Rose AJ, Reisman JI, Berlowitz DR, Kazis LE. Choices in the use of ICD-9 codes to 
identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution 
of CHADS2 scores. American Journal of Cardiovascular Disease. 2012;2(3):184-191. 
http://healthcaredelivery.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt 
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Appendix I:  Table 2 Logistic Regression Model to examine Predictors of Adherence in NOAC Patients at 
12 months 
 
AIM 1 MODEL 
FINAL_OCT.rtf
 
 
Appendix I:  Table 3 Logistic Regression Model to examine Predictors of Adherence in NOAC Patients at 
6 months 
 
AIM 1 MODEL 
FINAL_OCT 6M.rtf
 
 
Appendix I:  Table 4 Logistic Regression Model to examine Predictors of Adherence in NOAC Patients at 
12 months (with Interactions)  
AIM 1 (LR model 
with interactions at  
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Appendix I: Table 5 Distribution of days of supply variable for warfarin and NOACs  
a) .  WARFARIN (left) and NOAC (right) graph: 
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Appendix I: Table 6 Model Diagnostics  
 
AIM 1 (LR Model 
Diagnostics Plots).do
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Appendix I: Table 7 Variable Information  
Variable  Type Coding 
Charlson’s Comorbidity 
Index  
Categorical   0=CCI score 0 
1=CCI score 1-2 
2=CCI score 3 or more 
CHASD2SVASC Score  Categorical   1=low risk (1-2)  
2=mod-high risk (>2) 
Region  Categorical  STATES CT,ME,MA,NH,RI,VT,NJ,NY,PA = Northeast  
IN,IL,MI,OH,WI,IA,KS,MN,MO,NE,ND,SD = Midwest 
DE,DC,FL,GA,MD,NC,SC,VA,WV,AL,TN,KY,MS,AR,LA,
OK,TX = South 
AZ,CO,ID,NM,MT,UT,WY,NV,AK,CA,HI,OR,WA = West  
Insurance Type  Categorical   EPO=1 
 HMO=2 
 IND=3 
 OTH=4 
 POS=5 
 PPO=6 
Age  Continuous NA  
Beta blocker Use  
ARB Use  
Statin Use  
Ace Inhibitor Use  
 
Categorical 1= Yes  
0=No  
Gender  Categorical 1 =Male , 0 =Female  
Monthly Drug Cost  Categorical  1= ≤$400, 2=>$400 
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Appendix I: Table 8 Distribution of CHAD2VASC Score and CHADS2VASC  
 
 
Drug  
  
  
  
CCI Index  Warfarin N%  NOAC N% Total % 
0 404 (12.29) 311 (17.57) 715 14.14 
1 648 (19.71) 442 (24.97) 1090 21.55 
2 641 (19.50) 409 (23.11) 1050 20.76 
3 502 (15.27) 242(13.67) 744 14.71 
4 364(11.07) 172 (9.72) 536 10.6 
5 264(8.03) 89 (5.03) 353 6.98 
6 214 (6.51) 61 (3.45) 275 5.44 
7 123 (3.74) 25 (1.41) 148 2.93 
8 76 (2.31) 11 (0.62) 87 1.72 
9 33 (1.00) 7(0.40) 40 0.79 
10 13 (0.40) 0 (0.00) 13 0.26 
11 2 (0.06) 1 (0.06) 3 0.06 
12 1 (0.03) 0 (0.00) 1 0.02 
15 2 (0.06) 0 (0.00) 2 0.04 
Total 3287 1770 5057   
CHADS Score Warfarin N%  NOAC N% Total %  
1 436 (13.26) 278 (15.71) 714 14.12 
2 629 (19.14) 419 (23.67) 1048 20.72 
3 729 (22.18) 374 (21.13) 1103 21.81 
4 572 (17.40) 314 (17.74) 886 17.52 
5 429 (13.05) 177 (10.00) 606 11.98 
6 262 (7.97) 126 (7.12) 388 7.67 
7 157 (4.78) 60 (3.39) 217 4.29 
8 61 (1.86) 18 (1.02) 79 1.56 
9 12 (0.37) 4 (0.23) 16 0.32 
Total 3287 1770 5057   
 
  
 41 
 
BIBLIOGRAPHY 
1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: executive summary: a report of the 
American College of Cardiology/American Heart Association Task Force on 
practice guidelines and the Heart Rhythm Society. Circulation. 
2014;130(23):2071-2104. 
2. Prevention CDC. Atrial Fibrillation Fact Sheet. 2015; 
http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. 
Accessed 17 April, 2016. 
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation 
in adults: national implications for rhythm management and stroke prevention: the 
AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama. 
2001;285(18):2370-2375. 
4. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age 
distribution, and gender of patients with atrial fibrillation. Analysis and 
implications. Archives of internal medicine. 1995;155(5):469-473. 
5. DiPiro JT TR, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach,. 
New York: McGraw-Hill; 2011. 
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor 
for stroke: the Framingham Study. Stroke; a journal of cerebral circulation. 
1991;22(8):983-988. 
7. Association AH. Atrial Fibrillation Medications. 2014; 
http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Atr
ial-Fibrillation-Medications_UCM_423781_Article.jsp#.VxOtVPkrLIV. 
Accessed 17 April, 2016. 
8. Ciervo CA, Granger CB, Schaller FA. Stroke prevention in patients with atrial 
fibrillation: disease burden and unmet medical needs. The Journal of the 
American Osteopathic Association. 2012;112(9_suppl_2):eS2-eS8. 
9. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. 
Clinical Journal of the American Society of Nephrology. 2008;3(5):1504-1510. 
10. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial 
fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: 
American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines. Chest. 2012;141(2 Suppl):e531S-575S. 
11. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention 
in an elderly community population with atrial fibrillation (the Birmingham Atrial 
 42 
 
Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. 
Lancet. 2007;370(9586):493-503. 
12. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants 
used in stroke prevention in atrial fibrillation, venous thromboembolic disease, 
and acute coronary syndromes. Journal of the American Heart Association. 
2013;2(5):e000136. 
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in 
patients with atrial fibrillation. The New England journal of medicine. 
2009;361(12):1139-1151. 
14. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants 
opportunities and challenges. Arteriosclerosis, thrombosis, and vascular biology. 
2015;35(5):1056-1065. 
15. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in 
nonvalvular atrial fibrillation. The New England journal of medicine. 
2011;365(10):883-891. 
16. Delamater AM. Improving patient adherence. Clinical diabetes. 2006;24(2):71-
77. 
17. Osterberg L, Blaschke T. Adherence to medication. The New England journal of 
medicine. 2005;353(5):487-497. 
18. Cutler TW, Chuang A, Huynh TD, et al. A retrospective descriptive analysis of 
patient adherence to dabigatran at a large academic medical center. Journal of 
managed care pharmacy : JMCP. 2014;20(10):1028-1034. 
19. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. 
Dabigatran adherence in atrial fibrillation patients during the first year after 
diagnosis: a nationwide cohort study. Journal of thrombosis and haemostasis : 
JTH. 2015;13(4):495-504. 
20. Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed 
nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. 
Circulation. Cardiovascular quality and outcomes. 2013;6(5):567-574. 
21. Nelson WW, Song X, Coleman CI, et al. Medication persistence and 
discontinuation of rivaroxaban versus warfarin among patients with non-valvular 
atrial fibrillation. Current medical research and opinion. 2014;30(12):2461-2469. 
22. Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban 
therapy in atrial fibrillation patients-results from the Dresden non-interventional 
oral anticoagulation registry. Europace : European pacing, arrhythmias, and 
cardiac electrophysiology : journal of the working groups on cardiac pacing, 
 43 
 
arrhythmias, and cardiac cellular electrophysiology of the European Society of 
Cardiology. 2015. 
23. Lang K, Bozkaya D, Patel AA, et al. Anticoagulant use for the prevention of 
stroke in patients with atrial fibrillation: findings from a multi-payer analysis. 
BMC health services research. 2014;14:329. 
24. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in 
vitamin K antagonist–naive and–experienced cohorts with atrial fibrillation. 
Circulation. 2010;122(22):2246-2253. 
25. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring 
medication adherence. Springfield, VA: Pharmacy Quality Alliance. 2012. 
26. Stacy Wang ZH, Seth Traubenberg. Measuring Medication Adherence with 
Simple Drug Use and Medication Switching SAS Global Forum 2013 Pharma 
and Healthcare. 2013. 
27. Steiner JF, Fihn SD, Blair B, Inut TS. Appropriate reductions in compliance 
among well-controlled hypertensive patients. Journal of clinical epidemiology. 
1991;44(12):1361-1371. 
28. Zhu W-G, Xiong Q-M, Hong K. Meta-analysis of CHADS2 versus CHA2DS2-
VASc for predicting stroke and thromboembolism in atrial fibrillation patients 
independent of anticoagulation. Texas Heart Institute Journal. 2015;42(1):6-15. 
29. Kleinbaum DG. Applied regression analysis and other multivariable methods. 
Cengage Learning; 2013. 
30. Zhou M, Chang H-Y, Segal JB, Alexander GC, Singh S. Adherence to a Novel 
Oral Anticoagulant Among Patients with Atrial Fibrillation. Journal of managed 
care & specialty pharmacy. 2015;21(11):1054-1062. 
31. Al-Khalili F, Lindström C, Benson L. Adherence to anticoagulant treatment with 
apixaban and rivaroxaban in a real-world setting. Clinical Trials and Regulatory 
Science in Cardiology. 2016;18:1-4. 
32. Coleman CI, Tangirala M, Evers T. ADHERENCE TO RIVAROXABAN AND 
DABIGATRAN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS 
IN THE UNITED STATES. Journal of the American College of Cardiology. 
2016;67(13_S):755-755. 
33. McHorney CA, Crivera C, Laliberté F, et al. Adherence to non-vitamin-K-
antagonist oral anticoagulant medications based on the Pharmacy Quality 
Alliance measure. Current medical research and opinion. 2015;31(12):2167-
2173. 
 44 
 
34. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and 
longitudinal patient outcomes: insights from the veterans health administration. 
American heart journal. 2014;167(6):810-817. 
35. Coleman CI, Tangirala M, Evers T. Treatment Persistence and Discontinuation 
with Rivaroxaban, Dabigatran, and Warfarin for Stroke Prevention in Patients 
with Non-Valvular Atrial Fibrillation in the United States. PloS one. 
2016;11(6):e0157769. 
36. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin 
for atrial fibrillation. Circulation: Cardiovascular Quality and Outcomes. 
2010;3(6):624-631. 
37. Glader E-L, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary 
preventive drugs declines rapidly during the first 2 years after stroke. Stroke; a 
journal of cerebral circulation. 2010;41(2):397-401. 
38. Ho MH, Ho CW, Cheung E, et al. Continuation of dabigatran therapy in “real-
world” practice in Hong Kong. PloS one. 2014;9(8):e101245. 
39. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: 
focus on anticoagulants for the treatment and prevention of thromboembolism. 
Patient Prefer Adherence. 2010;4:51-60. 
40. American Heart Association. Cardiac Medications. 2016; 
http://www.heart.org/HEARTORG/Conditions/HeartAttack/PreventionTreatment
ofHeartAttack/Cardiac-Medications_UCM_303937_Article.jsp#.V4vRnPkrLIV. 
Accessed 17th July, 2016. 
 
  
 45 
 
MANUSCRIPT II 
 
SHORT AND LONG TERM IMPACT OF MEDICATION ADHERENCE ON 
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ABSTRACT 
Introduction: Novel Oral Anti-coagulants (NOACs including Dabigatran and 
Rivaroxaban) are new promising drugs which have shown better or similar efficacy to 
lower stroke risk and have fewer side effects compared to warfarin in the clinical trials.  
It has been substantially studied that better adherence to cardiac medications tends to 
reduce strokes and other related outcomes.  Prevention of stroke and other clinical 
outcomes can help reduce hospitalizations and its related burden on the healthcare 
system. To date, there have been very few studies which established a relationship 
between short and long-term adherence to NOACs and the reduction of ischemic stroke, 
major bleeding, Deep Venous Thrombosis and Pulmonary Embolism (DVTPE) and 
recurrent DVTPE risks. This research was the first to compare the impact of adherence 
on the stroke, bleeding, DVTPE and recurrent DVTPE risk in a propensity score based 
matched sample over a one-year period. 
Methods: A retrospective cohort study was conducted utilizing de-identified data from 
Optum® Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) (Jan 1, 2010 and 
Dec 31, 2012). database between January 1, 2010, and December 31, 2012. The study 
population was identified based on documentation of ≥ 1 diagnosis of atrial fibrillation or 
flutter ICD-9 code 427.31/32, 2 or more prescriptions of NOACs, age ≥18 years and 
CHA2DS2VASC score ≥1.  Adherence was calculated using PDC at 6, 9 and 12-month 
assessment periods. Patients were defined as adherent (≥80%) or non-adherent (<80%) 
and matched based on propensity score using Inverse Probability Treatment Weighting 
(IPTW). The risk of ischemic stroke, major bleeding DVTPE, and recurrent DVTPE was 
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calculated in post adherence assessment period and compared across groups. Adjusted 
estimates were derived using Cox and GLM model controlling for age, gender, region, 
CHA2DS2VASC score, Charlson’s Comorbidity Index (CCI), drug use at baseline, and 
insurance type. 
Results: The sample matched by IPTW provided better matching compared to caliper 
matching. At 12-month of adherence assessment, the three cohorts for bleeding, ischemic 
stroke, and DVTPE included 1617, 1651, 1364 patients respectively. The mean age of the 
sample was 65 years, 70% of the sample were males, and there was a higher proportion 
of patients with a CHA2DS2VASC score of 2 (23%). At 12 months, the incidence of 
bleeding, ischemic stroke, and DVTPE was 4.21%, 3.11%, and 1.11% respectively. 
Based on the multivariate analysis at 6 and 12 months of adherence assessment, the non-
adherence was significantly associated with 1.7 and 1.9 times increase in stroke risk 
respectively. Similarly, non-adherence was found to be significantly associated with 
elevated risk of recurrent DVTPE 3 and 6 months and DVTPE risk at 3, 6, 9 months.  
The risk of bleeding in non-adherent patients was slightly lower (HR 0.84 – 6 months, 
0.94 – 12 months) than risk in patients who are adherent to the NOACs. 
Conclusion: Impact of adherence on the reduction of stroke and DVTPE risk is 
noteworthy. The risk of bleeding is not significantly different between adherent and non-
adherent patients. Further studies on longer follow-up are warranted.  
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BACKGROUND 
Atrial Fibrillation (AF) is a common condition causing cardiac rhythm disturbance due to 
electro-physical or structural abnormality resulting in abnormal impulse formation.1  
In 2010, the prevalence of AF in the United States (US) was 2.7 to 6.1 million and is 
expected to grow between 5.6 and 12 million in 2050.2,3  Approximately 70% of patients 
with AF are between 65-85 years of age.4  AF is one of the key risk factors for ischemic 
stroke, increasing the risk up to 5-fold.5 
Stroke Risk and AF 
Stroke is the number four cause of mortality and a leading cause of long-term disability 
in the US. In the US, the stroke led to 1 in every 19 deaths in 2009, and a total treatment 
cost is estimated to be $38.6 billion per year.6  A stroke is caused due to an abrupt 
disruption of blood supply to the brain, which may be caused due to the bursting of the 
blood vessels (hemorrhagic stroke) or blocking by a clot (ischemic stroke).7  The risk 
factors for developing a stroke include, but not limited to, older age, cigarette smoking, 
obesity, cardiovascular disease and diabetes. One such heart-related condition, AF, an 
irregular heart rhythm, is a significant risk factor.8   
 Recent estimates in the US has AF affecting an estimated 2.6 to 3 million Americans 
with more than 795,000 people having a recurrent or a new stroke each year.9,10   
The risk of stroke due to AF also increases with older age, rising from 1.5 % in patients 
with an age of 50 to 59 years to 23.5 % for 80 to 89 years old patients.5  
Deep Venous Thrombosis and Pulmonary Embolism Risk (DVTPE)  
According to Center for Disease Control (CDC) estimates, 900,000 people are affected 
by DVTPE every year, which accounts for 60,000-100,000 deaths 11. DVT is caused 
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when there are clots in veins and PE is caused in continuation when the clots disintegrate 
and enter the arteries.  The incidence of the DVTPE increases with age to 1 in 100 in 
patients above the age of 80.  Together they are termed as Venous Thrombo-Embolism 
(VTE). Chronic disease, cancer, obesity, age, surgery, trauma, infection are some of the 
risk factors for DVTPE.12   
Patients with AF and stroke tend to develop DVTPE.  Hence, the use of anticoagulants as 
a preventative therapy for DVTPE and recurrent DVTPE is recommended.13 Low 
molecular weight heparin, fondaparinux and VKA anticoagulants (warfarin) are also used 
as pharmacological treatments.14  Lately, NOACs have shown promising results in a trial 
setting and are now approved for prevention of recurrent DVTPE.  
Bleeding Risk  
The use of anticoagulants is always associated with risk of bleeding-related 
complications. The difference in risk of bleeding was found to be non-significant 
between rivaroxaban and warfarin in the ROCKET-AF clinical trials (3.32 vs. 3.57).15 
Similar results with higher (but not significantly different) rates of bleeding with 
dabigatran were found compared to the warfarin.16   Major bleeding (including 
intracranial hemorrhages, GI bleeding, etc.) and its related costs lead to an enormous 
burden on the healthcare system. Also, based on a recent assessment by FDA adverse 
event systems, the NOACs have been associated with a high number of bleeding-related 
adverse events but the information on risk factors and age is unavailable. A limited 
number of real world studies have presented the evidence of a non-significant difference 
between warfarin and NOACs in regards to the bleeding risk.17 It is important to quantify 
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the bleeding risk in NOACs using real world data and understand the impact of adherence 
on the risk of bleeding.  
Risk Stratification  
The CHADS2 score has been used to quantify the risk of stroke or VTE in AF patients.  
It constituted a score of 0-6 based on risk factors for stroke including congestive heart 
failure (C), hypertension (H), , age > 74 years (A), diabetes (D) constituting 1 point each 
and previous occurrence of transient ischemic attack (TIA) or stroke with 2 points (S2).18  
The Antithrombotic Therapy and Prevention of Thrombosis, 9th edition, American 
College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines 
published in 2012 recommended aspirin as the antithrombotic agent of choice for AF 
patients at low risk of stroke (CHADS2 = 0), and oral anticoagulant therapy (OAC) for 
patients at intermediate to high risk of stroke (CHADS2 ≥ 1).19 Recently, based on the 
ACC/AHA/ESC guidelines (2006) for the management of patients with AF; CHADS2 
has been updated to CHA2DS2VASc (scored 0-9) which adds three more factors: vascular 
events or disease (V), age 65–74 years (A), and female gender (Sc).   The risk 
stratification is necessary for the AF patients since underuse of anticoagulants is 
prevalent in the high-risk population.20  Mostly clinician and patients tend to prefer to 
prescribe aspirin which is a safer and cheaper alternative to OAC.  Therefore, it is 
essential to assess the risk, for selection of appropriate treatment to achieve maximum 
benefits. 
Use of NOACs in stroke and DVTPE  
Medication options in AF include antiplatelets, anticoagulants, beta blockers, calcium 
channel blockers, sodium and potassium channel blockers.21  Anticoagulants significantly 
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decrease symptoms and health outcomes and are responsible for improved overall 
health.22 Warfarin is an oral vitamin K-antagonist approved in 1954 and has been a gold 
standard of care for more than 50 years. The variable dosing, frequent dose adjustments 
and narrow window for therapeutic use in warfarin therapy have prevented its the 
widespread use in patients. Moreover, interactions with concomitant medications, dietary 
restrictions, and the need for periodic monitoring has made warfarin use challenging for 
prescribers and patients.14  
NOACs include newly approved oral drugs: dabigatran “Pradaxa” (2010) and 
rivaroxaban “Xarelto” (2011), apaxiban and edoxaban. Overall, NOACs have proven to 
have better or similar efficacy in terms of reduction of stroke risks and non-inferior to 
warfarin for risk of bleeding complication.  NOACs are also prescribed to prevent 
recurrent DVTPE.23 The American Academy of Family Physicians and the American 
College of Physicians guidelines for VTE recommends 3 to 6 months of anticoagulant 
therapy following the first occurrence of a DVTPE.  
Relationship of Adherence with Stroke and Bleeding Risk  
 Retrospective observational studies have shown evidence that adherence to 
cardiovascular medications can reduce the hazard of stroke.24-26  According to an 
observational study with 73,527 patients on hypertensive medications in Finland, at 10 
years of follow-up, non-adherent patients had 3.01 (95% CI: 2.37–3.83) times higher 
odds of stroke death compared to adherent patients 25. The REasons for Geographic And 
Racial Disparities in Stroke (REGARDS) was a prospective, longitudinal cohort study 
with 30,239 subjects in US aged ≥45 years, concluded that non-adherent patients (based 
on Morisky scale) had 1.08 (1.04–1.14) times greater risk of stroke compared to the 
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patients who were adherent to the antihypertensive medications.27  For vitamin K 
antagonists (VKAs), non-adherence have been reported in the range of 22–58%.28 
According to a recent study including 4,188 Kaiser Permanente (US) patients with AF, 
more than 1 in 4 patients (26%) on warfarin discontinued therapy in the first year of 
therapy despite a low bleeding rate of 2.3%.29  In a  retrospective matched cohort study 
on 7539 patients with Kaiser Permanente Colorado (KPCO), the nonadherence to 
warfarin INR monitoring was associated with a modestly higher risk of 
thromboembolism (adjusted Hazard Ratio [HR] = 1.51; 95% confidence interval = 1.04 – 
2.20).30  In a study including 13,289 patients between January 2003 and December 2007 
using Thomson Reuters MarketScan Research Database, estimated drug use in 3 cohorts: 
patients with no warfarin exposure vs. Low PDC (<80%) and high PDC (≥80%). 
Moreover, the incidence of ischemic stroke, transient ischemic stroke (TIA) and 
gastrointestinal bleeding (GI) was lower for patients with PDC ≥ 0.80 compared to 
patients with PDC < 0.80.31 
Study Rationale and Justification 
Adherence is pivotal to the success of the therapy and is a crucial to ascertain the risk-
benefit of a recommended treatment. Although several studies have reported adherence to 
NOACs ranging from 40-94%, there is inadequate data on the impact of adherence on the 
stroke, bleeding, DVTPE and recurrent DVTPE risks.  This study examined an 
association between adherence to NOACs and risk of ischemic stroke, bleeding and 
DVTPE and recurrent DVTPE over a short and long-term period.  This study will be the 
first to match the adherent and non-adherent NOAC users based on propensity score to 
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compare the stroke, bleeding, DVTPE and recurrent DVTPE risks between the two 
cohorts.   
Hypothesis: Ho = There is no statistical difference in risk of stroke/bleeding/recurrent 
DVTPE/DVTPE between equivalent cohorts based on adherence, matched using 
propensity score in AF patients taking NOACs.  
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METHODOLOGY 
Study Design 
A retrospective cohort study design was utilized to calculate the adherence to NOACs 
using PDC and examine its impact on stroke, bleeding and DVTPE risk in NOAC 
patients. 
The study was conducted using medical and pharmacy claims data from January 1, 2010, 
to December 31, 2012, using a large-scale US managed care health plan affiliated to 
Optum® Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) Inc. database. 
The primary outcome of the data was a stroke, bleeding, and recurrent DVTPE risk 
compared across propensity score-matched adherent and non-adherent cohorts.   
Data source: The OPTUM database mainly includes medical claims, including inpatients 
and outpatient files and pharmacy claim data.  It contains details on dates of service, 
place of service, International Classification of Diseases, Ninth Revision, Clinical 
Modification ICD-9-CM/ICD-10 diagnosis codes, provider type, National Drug Code-
NDCs, drug quantity dispensed, days supplied, charges, deductibles, and copayments.  
The large US health plan database includes 14 million patients and 500,000 Medicare 
enrollees.  The member file constitutes the demographic data and eligibility information.  
The database comprehensively covers diverse geographical areas of US with most of its 
enrollees from the South and the Midwest.  All study data access was compliant with the 
Health Insurance Portability and Accountability Act.  To ensure the patient’s 
confidentiality, no identifiable protected health information was used or analyzed during 
the study.32   The data was accessed using the server at the University of Rhode Island 
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(URI) and analyzed using SAS EG 7.1.   The study was also approved by the Institutional 
review board at URI. 
Sampling design/procedures:   All patients between January 1, 2010, to December 31, 
2012, were identified.  Patients with warfarin, dabigatran or rivaroxaban (NOACs) were 
characterized using the NDC codes and brand name using REDBOOK. The index date 
was defined as the date of first prescription fill of the NOAC or warfarin in their 
respective drug cohort. Patients with at least two claims for the study drugs in the post-
index period were included. Patients were included based on at least one AF or atrial 
flutter diagnosis claim identified using the medical file (inpatient or outpatient) with an 
ICD-9 code of 427.31/427.32 during the pre-index period or 30 days within the index 
date. In addition to the AF patients, subjects with atrial flutter were also included since a 
large proportion of patients with atrial flutter also suffer from atrial fibrillation (overlap) 
and the recommended treatment is similar for AF and flutter in terms of prevention of 
stroke. Patients with age ≥ 18 years were included. Patients with concomitant use of 
warfarin and NOACs during the post-index assessment period were excluded. Few 
patients previously used warfarin in the pre-index period prior to starting the NOACs. 
Since, NOACs are also prescribed to fulfill the unmet need in few patients with prior 
warfarin use, to avoid exclusion of any NOAC user (and sample size considerations), the 
inclusion of these patients was based on the definition of “warfarin-naïve.” Based on the 
definition of ‘warfarin naïve’ in RELY trials, a patient was defined ‘warfarin-naïve’ if 
there was no use of warfarin 2 months before the index date (first fill) of NOACs or if the 
NOAC was used for a duration of at least 5 or more months.33  This criterion was to 
ensure we capture all NOAC users and avoid any potential bias in regards to prior 
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warfarin therapy for assessment of outcomes.  Thus, the index date of these “warfarin-
naïve” users was based on the first prescription fill of NOACs.  For sensitivity analysis, 
we also examined no use of warfarin 100 days before the index date as a threshold.  Data 
based on RELY trials has shown no heterogeneity between patients who have prior 
warfarin use (based on the above definition) and those with no prior warfarin therapy. 
Age was used as a continuous variable.  Furthermore, patients with CHA2DS2VASC 
score ≥1 (1-9) were identified using ICD-9 codes and included. CHA2DS2VASC 
characterizes the risk of stroke based on a score composed of (congestive heart failure, 
hypertension, age >75 years, diabetes, prior stroke, pulmonary or vascular disease, age 
[65-74 years], sex [as female]).  Please refer to Appendix Table 1 for ICD-9 codes. The 
patients with at least 6 months of pre and post index continuous eligibility with a 
permissible gap of 45 days were included in the cohort.  Patients with hyperthyroidism 
(ICD-9 242.9) were excluded from the patient cohort since it may be the probable cause 
of AF but is not related to cardiac pathways. (Please check Figure 2.1 in Tables and 
Figures II). Moreover, the final cohort was further sub-grouped based on each type 
outcome (Stroke, DVTPE, recurrent DVTPE, Bleeding) to avoid calculation of risk for 
competing outcomes. Patients in the cohort for recurrent DVTPE were defined based on a 
prior DVTPE occurrence in the pre-index period.  
Definition of Outcome  
The index date was defined as the date of the first prescription of NOACs. For calculation 
of PDC (exposure assessment), the patients were followed from one month after the 
index date to the end of assessment period (6,9,12 months) and were censored at the 
occurrence of an outcome (stroke, recurrent DVTPE, DVTPE and bleeding), 
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disenrollment from the healthcare plan, death, end of the study, whichever came first.  
Subjects with an outcome, such as ischemic stroke, DVTPE, bleeding between one month 
after the index date to the end of adherence assessment period (See figure 1) were 
excluded.  These patients were excluded to avoid assessment of exposure and outcomes 
in the same time frame and to set a sequence where exposure (adherence) precedes the 
outcome to establish a causal relationship. Adherence was counted after first 30 days of 
drug use since it overlapped with the window for diagnosis of atrial fibrillation.  
Outcomes were calculated from the end date of adherence assessment to outcome date, 
end of the study period or end of enrollment/death whichever occurred first. The patients 
were eligible to enter the cohort only once and were counted only for the first incident 
stroke, bleeding or post-index DVTPE episode. For assessment of recurrent DVTPE, only 
patients who had a previous DVTPE episode in the pre-index period (prior to the start of 
NOAC) were included in the cohort.  
Figure 2.1: Study design and timeline 
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Cumulative incidence of the study outcomes was calculated, and relative risk (RR= Risk 
of outcome among exposed/Risk of outcome among unexposed) and its 95% CI was 
computed as a risk estimate.   
The outcomes (ischemic stroke, major bleeding, DVTPE and recurrent DVTPE) were 
diagnosed based on ICD-9 codes (Please check the Appendix II Table 2.1 for a list of 
ICD-9) codes.  
Measurement of Adherence  
The medication possession ratio (MPR) and PDC are the most frequently used measures 
to estimate adherence. The denominator in MPR is defined based on the difference 
between first and the last fill and doesn’t account for discontinuation of the drug. 
Furthermore, overestimation of MPR might occur due to early refill and if patients take 
concurrent medications of the same class.   PDC is a preferred method to measure 
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adherence in the recent year since it accounts for non-persistence where the denominator 
is days between first fill and end of the study.34  Adherence was calculated using PDC. 
Adherent patients were defined based on a cutoff of PDC ≥ 80%.  
Propensity Score (PS) Matching  
Patient cohorts (adherent vs. non-adherent) were matched based on the propensity score 
to reduce any confounding due to study covariates and control selection bias.  The 
propensity score (PS) on stroke risk was calculated for each patient using a multivariate 
logistic regression controlling for covariates. Demographic variables including, gender, 
age (continuous variable), region, Charlson’s Comorbidity Index (CCI 0, 1-2, >2 based 
on parametric assessment), CHA2DS2VASC score (1-2 as low-risk, >2 as high-risk 
groups)35 were used as independent variables.  Pre-index cardiac medication use was 
defined based on AHA medication classes recommended for AF therapy. Moreover, the 
medication drug classes were also used as covariates in the pivotal dabigatran trial. The 
type of insurance was evaluated as possible confounders. The c-statistic was examined to 
understand how well the predicted probabilities derived from the model classified the 
patients into their original groups.36 
There are few ways to use the propensity score to compare outcomes:  matching or 
stratifying patients on the PS, inverse probability of treatment, weighting using the PS, 
and covariate adjustment in subsequent multivariate regression models.37 Matching is the 
most suitable method when the cases and control group are expected similar in size.38  
The patients were initially matched with 1:1 ratio using a specified caliper distance (e.g. 
equal to 0.02 of the standardized deviation of the logit of the propensity score).39-42  Since 
the adherence was high (>70%) among the cohorts, to prevent loss of sample size; the 
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patients were matched “with replacement” of controls.  Matching was evaluated by plots 
and by comparing descriptive characteristics.  In our data, due to large number of pseudo-
controls, optimum matching was not achievable using the caliper method.  
Inverse probability Treatment Weighting was then used where the patients in the 
treatment (adherent) group were assigned a weight of the direct inverse of their 
propensity score, and the control group (non-adherent) group patients were assigned the 
inverse of the propensity score subtracted from 1.43  The propensity weights were also 
trimmed for extreme values greater than 10.  The truncation of extreme values helped 
achieve better matching of the weights.44  The matching cohorts were compared using the 
plots and tabular results of the matched variables.  The IPTW weights thus obtained were 
used in the multivariate models (Cox and GLM Models) to predict the effect of the 
exposure (adherence) on the outcomes (stroke, bleeding, DVTPE).  
Multivariate models  
Using the IPTW matched data for each cohort, the incidence of ischemic stroke, bleeding, 
DVTPE and recurrent DVTPE and mean follow-up time were calculated. To quantify the 
association of adherence to the ischemic stroke, bleeding, DVTPE and recurrent DVTPE 
risk multivariate model were used.  The occurrence of an outcome (stroke, bleeding, 
DVTPE) was the dependent variable in the model and adherence was the primary 
independent variable. The Cox proportional hazard model or GLM models are preferred 
to calculate the relative risk.45  The relative risk was compared and graphically plotted 
using Kaplan Meier graphs. For GLM models, binomial models restrict the probabilities 
of an outcome to be greater than or equal to zero and thus leads to convergence issues.46  
Since the occurrence of stroke, DVTPE and bleeding are rare (with <10% of the sample); 
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to avoid the convergence issues, negative binomial, and Poisson distributions were 
preferred for GLM models.47    The models were checked for over-dispersion by 
checking the deviance and Pearson’s chi-square and were scaled in the model as required. 
To control for different follow-up time for outcomes for each patient, a semi-parametric 
Cox proportional hazard model was used by matching the cohorts using IPTW weights.  
The data was right-censored.  The Cox models were prior tested for proportionality of 
hazards by checking the Schoenfeld residuals, plots for log negative log of time and were 
evaluated for interaction with the adherence and time-varying covariate to check for the 
non-significant interaction term.  
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RESULTS 
We found a total of 25,120 users of NOACs and 149,359 users of warfarin within 
the study period. A total of 14,618 NOAC and 120,607 warfarin users had 2 or more 
prescription fills. Out of 14618 NOAC patients, 4332 patients had a prior warfarin use in 
the pre-index period, and the definition of ‘warfarin naïve’ was used to screen the 
patients. Based on the definition of ‘warfarin naïve’, 1107 out of 4332 patients were 
included as NOACs.  The sensitivity analysis using a threshold of 100 days instead of 60 
days led to a very minor change in the sample size and hence threshold of 60 days was 
retained and used.  A total of 1032 patients were excluded due to an overlap (concomitant 
use of warfarin and NOACs) in the post-index period.  Based on the other inclusion 
criteria (diagnosis of AF in pre-index period or 30 days within the index date, ≥18 years, 
continuous enrollment for 6 months pre and post-index, and CHA2DS2VASc ≥1), a total 
number of warfarin and NOAC patients were 8130 and 4758 respectively. 
To ascertain individual discontinuation dates (non-competing) for assessment based on 
each distinct occurrence of an outcome (stroke, bleeding, recurrent DVTPE and DVTPE) 
for each subject separately, 4 cohorts based on 4 outcomes were created.  For cohort with 
the outcomes such as a major bleeding, the total number of patients at 6, 9 ,12 months of 
adherence assessment were 3285, 2353 and 1617.  Similar sample sizes were observed 
for ischemic stroke cohort (N at 6 months of NOAC use- 3289, 9 months-2395 and 12 
months- 1651) and cohort for DVTPE (At 6 months of adherence assessment, N=3416, at 
9 months N= 2503 and at 12 months N=1739). According to American College of Chest 
Physicians (ACCP), 3-6 months of NOAC treatment is prescribed to prevent the 
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recurrence of DVTPE, hence the cohort to analyze recurrent DVTPE was based on 
patients who had prior DVTPE and 3 and 6 months of adherence assessment after the 
start of the treatment (N at 3 months – 4062, 6 months- 3440). Please check Table 2.2 in 
Tables and Figures for analysis population and sample size for each cohort. Figure 2.1 in 
Tables and Figures describes the cohort sample selection in detail. 
 
Overall Baseline Characteristics  
The mean age of the overall cohort was 65 years with more men (>70%) than females. 
The majority of the patients were either from the South or the Midwest (54%).  Most of 
the patients used (>60%) ‘Point of service’ as their health insurance type.  The proportion 
of patients (60% vs. 40%) with moderate-high risk (based on CHA2DS2VASC score > 2) 
was higher compared to the low-risk (1-2) patients. Most (>82%) of the patients had at 
least 1 comorbidity. The statins (>60%) and ace-arb inhibitor use (>51%) were most 
commonly used as other medication in the pre-index period.  Please refer to Table 2.2 in 
Tables and Figures II for details on demographic characteristics.  
 
Adherence measured by PDC 
Adherence was measured at 6, 9 and 12 months in the adherence assessment period 
as described in the METHODOLOGY section. Patients were termed adherent based on 
PDC ≥80%.  The proportion of adherent patients for bleeding cohort at 6, 9, 12 months 
was 82.7%, 76.2%, 77.9% respectively.  A similar proportion of adherence was observed 
for ischemic stroke (82.6%, 76.2%, 78.3%) and DVTPE (82.7%, 76.4%, 78.4%) cohorts 
at 6, 9, 12 months.  Overall, the adherence to NOACs decreased over a period of 9 
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months and stabilized over the final 12-month assessment.  Please refer to Table 2.1 in 
Tables and Figures II for adherence estimates.  
 
Matched Cohorts 
First, the propensity score matching was performed using a caliper matching of 0.2 and 
“without replacement” which led to very low sample size due to fewer controls (high 
adherence).  Propensity score matching was tried using caliper matching of 0.2 and “with 
replacement” of controls. A higher proportion of adherence (>70%) led to multiple 
pseudo-matching controls with poorly matched cohorts.  To remove the bias with 
minimal loss of patients, IPTW method was used to match the patients based on the 
propensity score. The covariates used in the propensity score model (Age, gender, 
insurance, region, CHAD2VASC score, CCI, cardiac drug use – Appendix Table 2) were 
compared between the matched adherent and non-adherent cohorts. Based on the non-
significant p-values (>0.1), IPTW provided better matching with marginal effect on the 
sample size.  Further results are presented and interpreted based on IPTW cohorts. Please 
See Table 2.2 in Tables and Figures II to compare matched cohorts between caliper and 
IPTW techniques.  
 
Bleeding Risk and Adherence  
The overall incidence of bleeding in the cohort was 5.91% and 4.21% based on 6 and 12-
month adherence assessment.  The proportion of bleeding after 6 months of adherence 
assessment was slightly higher in adherent patients compared to non-adherent patients 
(6.34 vs. 5.29 p=0.165), but the association was not statistically significant.  Similarly, 
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after long-term use (12 months), adherent patients were more likely (4.41 vs. 3.99 
p=0.676) to have an occurrence of bleeding as compared to the adherent patients, but the 
association was non-significant. On an average, the total follow-up time for outcome 
evaluation was 8.8 months after 6 months of adherence assessment and 6.7 months after 
12 months of adherence assessment. Please see Table 2.3 in Tables and Figures II for 
frequencies and relative risks based on IPTW matched data.  
The association was further examined using multivariate Cox proportion hazards models 
(to control for the variable time) and GLM models adjusted by the IPTW weights.  
Based on the multivariate Cox model, at the end of 12-month usage, non-adherent 
patients were marginally less likely to experience a major bleeding [HR=0.940 (0.583-
1.515 p=0.798)] compared to the adherent patients. A similar result was obtained using 
Poisson model (RR=0.905 p=0.683) for non-adherence, which led to the fewer bleeding 
events, but the relationship was not statistically significant (Please see Table 2.5 in 
Tables and Figures II). This trend was also consistent for short-term (6-month) use all 
three models (Cox and GLM- Please see Table 2.4/2.5 in Tables and Figures II).  Overall, 
the adherence was modestly associated with elevated bleeding but was not significantly 
different between adherent and non-adherent patients. Hence, higher adherence in 
NOACs might not significantly increase the risk of bleeding. 
 
Risk of Ischemic Stroke and Adherence  
The incidence of ischemic stroke was 3.11% based on the adherence assessment period of 
12 months. The proportion of ischemic stroke were lower among adherent patients at 6, 
9, and 12 months (2.63 vs. 4.39; 2.62 vs. 3.96; 2.19 vs. 4.12) respectively, a significant 
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association between adherence and stroke risk was observed at 6 and 12 months of 
adherence assessment. At 6-month drug use, non-adherent patients were 1.66 times 
(1.1509 – 2.4121) more likely to experience an ischemic stroke compared to the adherent 
patients. Similarly, non-adherent patient at 12 months were 1.88 times more likely to 
have an ischemic stroke. The total follow-up period for assessment of ischemic stroke 
was 9.08 months for patients with 6-month of NOAC use and 6.82 months for 12-month 
drug use. Please see Table 2.3 in the Tables and Figures II for frequencies and relative 
risks based on IPTW.  
A Cox proportional hazards model for risk of ischemic stroke after 6 and 12-month of 
drug use was high among non-adherent patients with a hazards ratio of 1.71 (CI-1.178-
2.501, p=0.0049) and 1.94 (CI- 1.097-3.427, p=0.0226). 
Both GLM and Cox models for 9 and 12-month showed a similar trend (higher risk of 
stroke among non-adherent patients) with non-significant estimates. (Please see Table 
2.4/2.5 in Tables and Figures II). Based on 6 and 12-month adherence assessment, non-
adherence to NOAC treatment was significantly associated with elevated risk 
[RR=1.6661, p=0.0078 and RR=1.8813, p=0.0295 respectively] of ischemic stroke risk 
compared to the adherent patients. (Please see Table 2.5 in Tables and Figures II). 
Overall, adherence to NOACs is protective for an incidence of ischemic stroke over the 
short-term while providing less significant effect over a long-term drug use.  
 
Risk of DVTPE and Adherence  
At 12 months, the incidence of DVTPE was 1.11%. The follow-up time for outcomes 
post 6 and 9-month adherence assessment was 9.08 months and 6.82 months.   
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The incidence estimates for DVTPE were higher among non-adherent compared to 
adherent patients based on 6 (1.04% vs 2.71%), 9 (0.44 vs. 2.36%), and 12-month (0.43% 
vs. 1.84%) adherence respectively. Please see Table 2.3 in Tables and Figures II.  
Based on multivariate results using the Cox model, non-adherence had a significant [HR 
– 2.703 (1.572-4.646)] association with risk DVTPE based on 6 months of NOAC usage. 
Patients who were non-adherent based on 12-month assessment had a higher risk [HR -
4.603 (1.508-14.053)] of DVTPE compared to the non-adherent patients. (Table 2.5 in 
Tables and Figures II). 
Using the Poisson model, the adjusted estimated hazard of DVTPE in non-adherent 
patients were significantly higher (RR – 2.603, 5.316, 4.287) based on 6, 9 12-month 
adherence compared to the adherent patients which corroborated the results based on the 
Cox models.  The high hazard ratios and risk estimates from the GLM models can be 
attributed to very few numbers of patients with outcomes in this cohort with 12 months of 
drug use. (Please see Tables 2.4/2.5 Tables and Figures II for multivariate results). 
 
Risk of recurrent DVTPE and Adherence  
Although the incidence of recurrent DVTPE was very low (0.87% at 3 months’ drug use 
and 0.55% for 6 months’ drug usage), adherence was significantly associated with the 
reduction of recurrent DVTPE in patients who already had a pre-index occurrence.  This 
association was observed for both 3-month and 6-month adherence to NOACs (incidence 
of recurrent DVTPE for adherence vs. non-adherence: 0.35 vs. 1.53 at 3 months and 0.08 
vs. 1.08 at 6 months) respectively, where non-adherence increased the risk of DVTPE.  
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Based on a multivariate Cox model, non-adherence was significantly associated with 
increased risk of recurrent DVTPE [HR=6.178 (1.845 -20.682)] after 6 months of 
treatment. (Table 2.5 Tables and Figures II). Poisson model suggested higher risk (HR – 
4.342 p=0.0003) of recurrent stroke in non-adherent patients based on 6-month 
adherence. The adherence to the NOAC therapy provides a clear trend of secondary 
preventive effect for recurrent DVTPE over a period of 3-6 months after the therapy, 
although the low incidence of outcomes in the study might be responsible for the inflated 
estimates.  
Model Testing 
Overall, the model fit examined with the help of deviance for GLM models using Poisson 
distribution was good with Pearson’s chi-square <1 (no re-scaling using adjusting of 
Pearson’s or deviance residual was required). Schoenfeld residuals to assess the 
proportionality of hazard were mostly parallel for hazards over time for adherence as a 
covariate.  The models were also tested by adding an interaction term for adherence and 
follow-up time to evaluate the effect; non-significant estimates on the interaction term 
helped confirm the assumption of proportional hazards. The GLM models using negative 
binomial distribution mostly converged except models for recurrent DVTPE at 3 and 6 
months of therapy.   
 
 
  
 69 
 
DISCUSSION 
Based on large real-world cohort, our results indicate that there is a significant 
association of adherence to NOAC therapy and a reduction in ischemic strokes and 
DVTPE at 6 and 12 months and recurrent DVTPE after 3 and 6 months of NOAC 
treatment.  Furthermore, based on our results, higher adherence might not lead to 
significant increase in bleeding events. 
The adherence to NOACs in our study was greater than 70%, which is consistent with the 
literature 48,49.  The overall follow-up to assess outcomes was more than 8.5 months and 
6.5 months for a 6-month and 12-month adherence assessment (exposure) period 
respectively, for the NOAC drugs. This will be the first study to examine the impact of 
adherence on outcomes such as major bleeding, ischemic stroke, DVTPE and recurrent 
DVTPE using propensity score-matched cohorts.  Since the NOACs have already shown 
better efficacy results against warfarin, evidence that adherence is more beneficial to 
reduce the outcomes may lead to even greater cost savings.  Our study not only concurs 
with the previous findings in hypertensive drug classes that better adherence to the drug 
leads to reduced stroke risk and other cardiac-related events but also translates the 
evidence to NOACs (anticoagulants).25,50  
Overall, we found a higher incidence of ischemic stroke and bleeding in our real -world 
study as compared to the estimates found in the clinical trials. It was noteworthy that the 
number of bleeding events was not significantly different between adherence cohorts for 
the short and long-term use of NOACs.  Our estimates of major bleeding were 
comparable to (4.21%) to previous studies which reported the occurrence of major 
bleeding in patients taking NOACs 51.  In a study by Mercaldi et.al on 2 million patients 
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from Centers for Medicare and Medicaid Services, the rate of ischemic stroke was 3.9 per 
100 patient-years, and major bleeding 7.58 per 100 patient-years based on a follow-up of 
approximately 2 years 52.  In a study based on 2010-2011 data for Medicare beneficiaries, 
the incidence of major bleeding was higher in dabigatran vs. warfarin (9% vs.5.9%).53  In 
a recent study based on 64,661 AF patients in the OPTUM database, the overall incidence 
of major bleeding was 3.7 per 100 person-years which seemed consistent with our 
estimates.54 
 Our study reported an incidence of 3.11% for stroke at 12 months of adherence. In 
another retrospective study on 2006-2008 Medicare beneficiaries, the stroke rate of 
patients with AF was 3.3% which is consistent with our estimate.55  A study using 
Medicare population (N= 134 414) reported fewer stroke rates in dabigatran as compared 
to warfarin (1.12 vs. 1.34 per100 person-years).56  The stroke rates for dabigatran using a 
Medicare claims database (N= 64 935) was 1.73 per 100 person-years.57  The slightly 
higher incidence of stroke in our study may be due to a higher proportion of patients with 
moderate-high risk of stroke (60%) in the overall population.  
A study based on combined data from MarketScan and OPTUM reported the incidence 
rate of DVTPE as 0.58.58   The incidence of recurrent DVTPE in our study ranged from 
0.55-0.87 over 3 and 6 months of NOAC use. 
We used large claims data since our hypothesis and study designed required to have a 
large sample. To address the selection bias and residual confounding, the adherence 
based cohorts were matched based on stroke risk (CHAD2SVAS2C) and other covariates 
including CCI, age, gender, insurance, region, prior cardiac drug use. The issue in regards 
to the multiple pseudo-controls due to less control as compared to cases was addressed 
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using IPTW, which helped to achieve better matching.  The study design helped to 
achieve a sequential order of exposure preceding the outcome, but this led to an exclusion 
of outcomes occurring between index and end of adherence assessment. Furthermore, 
adherence assessment based on 3, 6, 9, and 12-month windows might lead to truncation 
of the data. Therefore, the windows were kept close at every 3 months.  ICD-9 codes 
were selected based on an in-depth literature survey where only those reported to have a 
value of ≥ 90 Positive Predictive Value (specificity and sensitivity) were included.  This 
criterion helped us to have a better confidence in the selection of patients and avoid 
misclassification.  Sensitivity analysis using the Poisson model helped to validate the 
results over a short and long term (6, 9, 12-months).   Recently in Feb 2016, a manuscript 
was published based on the study, which examined an effect of adherence on stroke. The 
adherence estimated with PDC was low (47%) which can be attributed to longer follow-
up time as compared to our study.  Furthermore, the study found adherence is protective 
of stroke risk at 3, 6, and >6 months which agrees with our results.54  Our study is unique 
in a way where the outcomes, including stroke, bleeding and DVTPE are compared 
between propensity-matched adherence based cohort which controls for the selection 
bias. Also, our study will be the first to understand the effect of adherence on DVTPE 
and recurrent DVTPE. 
It should be acknowledged that OPTUM is mostly a commercial database under-
represented by Medicare population (above 65 years). Over 65% of the sample was 
represented by males, predominantly from the South or the Midwest and the database 
lacked information in regards to the race, ethnicity and reason for discontinuation of 
therapy.  
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Although in the analysis, clinical variables (e.g. INR values, left ventricular ejection 
fraction, body mass index) were not included, clinical markers of severity such as 
CHA2DS2VASC and CCI helped to control for risk due to hypertension, prior 
cardiovascular disease, diabetes and other co-morbidities. Prior use of cardiac drugs was 
also accounted. However, aspirin use was not comprehensively captured in the claims 
database due to availability as an Over the Counter (OTC) drug.  Since the study period 
for this analysis was from 2010-2012, a limited follow-up time was achievable for 
outcomes to occur.  Moreover, the newer drugs apaxiban and edoxaban came into the 
market after 2012 were not included. Despite these limitations, the study provides 
valuable evidence in regards to adherence to NOACs and its short and long-term effects 
on bleeding, ischemic stroke and recurrent DVTPE controlling for other factors.  
 
CONCLUSION 
Adherence to NOACs is suboptimal for anticoagulation control and decreases over time. 
Overall, adherent NOAC patients had lower rates of ischemic stroke, DVTPE, and 
recurrent DVTPE compared to non-adherent patients. Short and long term risk of 
bleeding was not significantly different between adherent and non-adherent patients.  
The short and long-term estimates of adherence to NOACs and its effect on the risk of 
bleeding, stroke, and DVTPE as observed in our study may help the healthcare providers 
and managed care organizations to compare risk-benefits of prescribing NOACs. The 
findings will further help to provide optimal care to patients by improving adherence and 
reduce HCRU and healthcare costs. Future research on adherence to NOACs including 
the newer drugs and longer follow-up times is warranted.  
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Figure 2.2: Cohort Selection Based on Inclusion and Exclusion Criteria  
 
 
 
 
  
Patients with ≥2 fills  
NOAC = (N=14618) and Warfarin (N=120607)  
Adult patients Age ≥ 18  
NOAC (N=10345) and Warfarin (N=114230) 
 
Continuous enrollment for 6 months’ pre-index and 6 months’ post 
index (45 Day gap)   
Warfarin (N=29269), NOAC (N=5790) 
 
NOAC  
 
Ischemic Stroke Cohort  
Bleeding Cohort  
DVTPE Cohort  
Recurrent DVTPE Cohort  
Exclude Patients with ≤1fills  
Adult patients with any NOAC Drug Use (N=25,120) 
Warfarin N = (149395) 
1. if warfarin is used before 
NOAC: if a patient has warfarin 
prescription < 60 days or gap 
between warfarin and NOAC is 5 
months or greater; then the 
patient is termed as warfarin 
naive 
2. if warfarin use with or after 
NOAC; then patient is 
excluded (out of 14618 NOAC 
patients, 4332 where warfarin 
was used prior to NOAC in the 
pre-index period and the 
definition of warfarin naïve was 
used. Based on warfarin naïve 
definition 1107 patients were 
included as NOACs, 1032 were 
excluded due to overlap in the 
post index period) 
 
Diagnosis of Atrial Fibrillation (427.31) or Flutter (427.32) in pre-index or 
within 30days of index date; Warfarin (N=8834) NOAC (N=5164) 
CHA2DS2VASc ≥ 1;  
Warfarin (N=8130) NOAC (N=4758) 
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      Table 2.1: Adherence for Cohorts at Varying Time-points  
 
 
 
 
 
 
 
Outcome cohort  
 
Time point Category  N  % Adherence 
Bleeding (n=3285) 6 months Non-Adherent 569 17.32 
  Adherent  2716 82.68 
Bleeding (N=2353) 9 months Non-Adherent 561 23.84 
  Adherent  1792 76.16 
Bleeding (N=1617) 12 months Non-Adherent 357 22.08 
  Adherent  1260 77.92 
Ischemic Stroke (N=3289) 6 months Non-Adherent 573 17.42 
  Adherent  2716 82.58 
Ischemic Stroke (N=2395) 9 months Non-Adherent 571 23.84 
  Adherent  1824 76.16 
Ischemic Stroke (N=1651) 12 months Non-Adherent 359 21.74 
  Adherent  1292 78.26 
Recurrent DVTPE (N=4062) 3 months Non-Adherent 638 15.71 
  Adherent  3424 84.29 
Recurrent DVTPE (N=3440) 6 months Non-Adherent 592 17.21 
  Adherent  2848 82.79 
DVTPE (N=3416) 6 months  Non-Adherent 588 17.21 
  Adherent  2848 82.79 
DVTPE (N=2503) 9 months  Non-Adherent 590 23.57 
  Adherent  1913 76.43 
DVTPE (N=1739) 12 months  Non-Adherent 375 21.56 
  Adherent  1364 78.44 
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Table 2.2: Comparison of Propensity Matched Cohort by Caliper and IPTW  
  Caliper Matching IPTW 
Variable 
Description 
Statistic 
Response 
Category 
Total (N= 
2,520) 
Adherent 
(N= 1,260) 
Non-Adherent 
(N= 1,260) 
P-value 
(Chi-sq) 
Total        
(N= 1,617) 
Adherent 
 (N= 1,260) 
Non-Adherent 
 (N= 357) 
P-value 
(Chi-sq) 
Age at index N 2520 1,260 1,260 <0.3029 1617 1,260 353 0.6601 
 Mean (SD) 65.84 (10.65) 65.62(10.05) 66.06 (11.21)  64.83 (10.45) 64.89 (8.15) 64.6 (16.93)  
 Median(IQR) 64(58,73) 64 (59,73) 64 (57,72)  63 (58,72) 63 (59,72) 63 (57,72)  
 Range 34,86 34,86 34,86  26,86 34,86 26,86  
Gender Female 839 (33.29) 380 (30.16) 459 (36.43) <0.001 491 (30.46) 252 (30.48) 240 (30.44) 0.9865 
 Male 1,681 (66.71) 880 (69.84) 801 (63.57)  1,122 (69.54) 574 (69.52) 548 (69.56)  
Insurance type EPO 261 (10.36) 134 (10.63) 127 (10.08) <0.001 192 (11.88) 96 (11.69) 95 (12.09) 0.4507 
 HMO 100 (3.97) 69 (5.48) 31 (2.46)  101 (6.28) 50 (6.08) 51 (6.50)  
 IND 450 (17.86) 200 (15.87) 250 (19.84)  230 (14.24) 121 (14.62) 109 (13.84)  
 POS 1,550 (61.51) 790 (62.70) 760 (60.32)  1,029 (63.78) 520 (62.95) 509 (64.65)  
 PPO 159 (6.31) 67 (5.32) 92 (7.30)  62 (3.82) 38 (4.66) 23 (2.93)  
Region Midwest 530 (21.03) 286 (22.70) 244 (19.37) 0.0001 327 (20.25) 177 (21.41) 150 (19.04) 0.5577 
 Northeast 274 (10.87) 124 (9.84) 150 (11.90)  152 (9.40) 81 (9.81) 71 (8.97)  
 South 1,181 (46.87) 635 (50.40) 546 (43.33)  863 (53.52) 430 (52.13) 433 (54.97)  
 West 535 (21.23) 215 (17.06) 320 (25.40)  272 (16.83) 137 (16.65) 134 (17.02)  
CHA2D2VASC 
Score 
Low risk 977 (38.77) 483 (38.33) 494 (39.21) 0.6529 653 (40.51) 332 (40.21) 322 (40.83) 0.8014 
 Mod-high risk 1,543 (61.23) 777 (61.67) 766 (60.79)  960 (59.49) 493 (59.79) 466 (59.17)  
CCI category CCI score 0 484 (19.21) 226 (17.94) 258 (20.48) 0.0024 290 (17.99) 151 (18.26) 140 (17.72) 0.8298 
 CCI score 1-2 1,171 (46.47) 629 (49.92) 542 (43.02) 
 
 789 (48.91) 407 (49.34) 382 (48.46)  
  
77 
 
 CCI score 3 
and+ 
865 (34.33) 405 (32.14) 460 (36.51)  534 (33.10) 267 (32.40) 266 (33.82)  
Statin use No 1,068 (44.46) 513 (40.71) 555 (44.05) 0.0846 787 (48.76) 396 (47.96) 391 (49.61) 0.5078 
 Yes 1,334 (55.54) 688 (54.60) 646 (51.27)  826 (51.24) 430 (52.04) 397 (50.39)  
ACE ARB 
inhibitor 
No 1,159 (48.25) 567 (45.00) 592 (46.98) 0.3073 835 (51.79) 420 (50.83) 416 (52.79) 0.4293 
 Yes 1,243 (51.75) 634 (50.32) 609 (48.33)  778 (48.21) 406 (49.17) 372 (47.21)  
Beta-blocker use No 1,685 (70.15) 836 (66.35) 849 (67.38) 0.5621 1,145 (70.98) 582 (70.55) 563 (71.43) 0.6962 
 Yes 717 (29.85) 365 (28.97) 352 (27.94)  468 (29.02) 243 (29.45) 225 (28.57)  
CCI- Charlson’s comorbidity Index, HMO – Health maintenance organization, PPO- Preferred provider organization, EPO -  Exclusive provider 
organizations, IND- Independent, POS-Point of service, ARB- Angiotensin Receptor Blocker, ACE- Angiotensin-converting enzyme 
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Table 2.3: Incidence Estimates for Outcomes in Propensity (IPTW) based Adherence Groups  
Adherence  Mean (SD) 
Follow up 
time 
(months) 
N Major 
Bleeding 
N Adherent N Non-
adherent 
Relative Risk     Chi-sq 
p-value 
          
6 months 8.80 (5.31) 3249 192 (5.91) 1746 112 (6.34) 1503 79 (5.29) 0.8214 (0.6216-1.0855) 0.1657 
9 months 7.74 (4.49) 2348 122 (5.27) 1195 63 (5.54) 1153 59 (4.99) 0.9653 (0.6832- 1.3639) 0.8414 
12 months 6.67 (3.63) 1613 68 (4.21) 825 36 (4.41) 788 32 (3.99) 0.90935 (0.5675-1.443) 0.6764 
          
Adherence  N Ischemic 
Stroke 
N Adherent N Non-
adherent 
Relative Risk     Chi-sq 
p-value 
          
6 months 9.08 (5.31) 3252 112 (3.44) 1755 46 (2.63) 1496 66 (4.39) 1.6661 (1.1509-2.4121) 0.0062 
9 months 7.91 (4.53) 2389 78 (3.28) 1218 31 (2.62) 1171 46 (3.96) 1.5128 (0.9709 –2.3573) 0.0652 
12 months 6.82 (3.64) 1641 51 (3.11) 856 19 (2.19) 785 32 (4.12) 1.8812 (1.0737-3.2966) 0.0246 
          
Adherence  N Recurrent 
DVTPE 
N Adherent N Non-
adherent 
Relative Risk     Chi-sq 
p-value 
          
3 months 11.64 (5.48) 3995 35 (0.87) 2234 8 (0.35) 1761 26 (1.53) 4.34 (1.9656-9.5956) 0.0001 
6 months 9.22 (5.32) 3394 18 (0.55) 1851 3 (0.08) 1543 15 (1.01) 5.892 (1.7638-19.6866) 0.0010 
          
Adherence   N DVTPE N Adherent N Non-
adherent 
Relative Risk     Chi-sq 
p-value 
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6 months  9.15 (5.32) 3372 51 (1.68) 1836 19 (1.04) 1536 42 (2.71) 2.6035 (1.5212-4.4555) 0.0003 
9 months 7.97 (4.51) 2497 35 (1.38%) 1272 6 (0.44) 1224 29 (2.36) 5.3167 (2.1656 -13.052) <.0001 
12 months  6.85 (3.64) 1730 19 (1.11%) 898 4 (0.43) 832 15 (1.84) 4.2873 (1.4105-13.0314) 0.0050 
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Table 2.4.  Cox Model for Association of Adherence with Bleeding using the IPTW Matched Data  
 
 
 
 Independent Variable 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Pr > Chi
Sq 
Bleeding at 6 months Adherence vs Non Adherence 0.844 0.633 1.125 0.2478 
Bleeding at 9 months Adherence vs Non Adherence 0.989 0.694 1.411 0.9527 
Bleeding at 12 months Adherence vs Non Adherence 0.940 0.583 1.515 0.7982 
      
Stroke at 6 months Adherence vs Non Adherence 1.716 1.178 2.501 0.0049 
Stroke at 9 months Adherence vs Non Adherence 1.519 0.968 2.385 0.0690 
Stroke at 12 months Adherence vs Non Adherence 1.939 1.097 3.427 0.0226 
      
Recurrent DVTPE at 3 months Adherence vs Non Adherence 4.568 2.062 10.122 0.0002 
Recurrent DVTPE at 6 months Adherence vs Non Adherence 6.178 1.845 20.682 0.0031 
      
DVTPE at 6 months Adherence vs Non Adherence 2.703 1.572 4.646 0.0003 
DVTPE at 9 months Adherence vs Non Adherence 5.531 2.245 13.627 0.0002 
DVTPE at 12 months Adherence vs Non Adherence 4.603 1.508 14.053 0.0073 
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Table 2.5.  Poisson and Negative Binomial Model Results for Association of Adherence with Bleeding using the IPTW Matched Data  
 
  Poisson Negative Binomial 
 Independent Variable  Estimate Confidence Limits 
Pr > Chi
Sq Estimate Confidence Limits 
Pr > Chi
Sq 
Bleeding at 6 months Adherence vs Non Adherence  0.8214 0.6164 1.0947 0.1794 0.8016 0.5381 1.1940 0.2766 
Bleeding at 9 months Adherence vs Non Adherence  0.9653 0.6769 1.3767 0.8455 0.8639 0.5604 1.3318 0.5077 
Bleeding at 12 months Adherence vs Non Adherence  0.9053 0.5618 1.4590 0.6830 0.8141 0.4457 1.4869 0.5033 
          
Stroke at 6 months Adherence vs Non Adherence  1.6661 1.1436 2.4275 0.0078 1.5965 0.9992 2.5510 0.0504 
Stroke at 9 months Adherence vs Non Adherence  1.5128 0.9639 2.3743 0.0718 **    
Stroke at 12 months Adherence vs Non Adherence  1.8813 1.0648 3.3241 0.0295 1.5319 0.7817 3.0019 0.02140 
          
Recurrent DVTPE at 3 months Adherence vs Non Adherence  4.3429 1.9608 9.6192 0.0003 **    
Recurrent DVTPE at 6 months Adherence vs Non Adherence  5.8926 1.7604 19.7238 0.0040 **    
          
DVTPE at 6 months Adherence vs Non Adherence  2.6034 1.5148 4.4745 0.0005 2.4260 1.2864 4.5750 0.0062 
DVTPE at 9 months Adherence vs Non Adherence  5.3167 2.1582 13.0976 0.0003 **    
DVTPE at 12 months Adherence vs Non Adherence  4.2873 1.4049 13.0835 0.0106 4.9690 1.7241 14.3210 0.0030 
*: The relative Hessian convergence criterion was greater than the limit of 0.0001. The convergence is questionable. Negative of Hessian not positive 
definite 
** Algorithm didn’t converge  
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APPENDICES II 
 
Appendix II: Table 1 ICD-9 Diagnosis codes 
  
  ICD-9 Codes  
AF Diagnosis  Atrial Fibrillation and Flutter 427.31, 427.32 
Hypothyroidism 240.9 
CHA2DS2VASC 
Score  
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.03, 404.11, 404.13, 404.91, 404.93, and 
428.x, 518.4 
Diabetes 250.x, 357.2, 362.0, and 366.41 
Hypertension 401.x, 402.x, 403.x, 404.x, and 405.x 
Stroke TIA 433,434, 435, 436 
 
Vascular disease 410,411,412, 413, 414, 443.8, 443.9 
 
Major Charlson’s 
Comorbidity Index 
diagnosis  
Myocardial Infarction 410, 412 
CHF 428 
Cerebrovascular disease  430-438 
COPD 490-496, 500-505, 506.4 
Paralysis  342, 344.1 
Chronic Renal failure 582, 585, 586, 588, 583.0 – 583.7 
Ulcers 531-534 
Cirrhodites 5712, 5714, 5715, 5716 
AIDs 042,044 
Metastatic tumor  196.0-199.1, 196.x 
Major Bleeding  GI 456.0, 456.20, 530.21, 530.7, 530.82, 531.0x, 
531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 
532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 
533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 
535.01, 535.11, 535.21, 535.31, 535.41, 
535.51, 535.61, 535.71, 537.83, 537.84, 
562.02, 562.03, 562.12, 562.13, 568.81, 
569.3, 569.85, 578.x 
Intracranial  430, 431, 432.x, 852.x, 853.x 
Other sites 423.0, 459.0, 596.7, 599.71, 719.1x, 784.8, 
786.3 
Ischemic Stroke  433.x1, 434.x1, or 436 
DVT   45111, 45119, 4512, 45181, 4519, 45340, 
45341, 45342, 4538, 4539 
PE   4151, 41511, 41519 
Rothendler JA, Rose AJ, Reisman JI, Berlowitz DR, Kazis LE. Choices in the use of ICD-9 codes to 
identify stroke risk factors can affect the apparent population-level risk factor prevalence and distribution 
of CHADS2 scores. American Journal of Cardiovascular Disease. 2012;2(3):184-191. 
http://healthcaredelivery.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt 
http://www.qualityindicators.ahrq.gov/Downloads/Modules/PSI/V44/TechSpecs/PSI%2012%20Postoperati
ve%20PE%20or%20DVT%20Rate.pdf 
Yao, Xiaoxi, et al. "Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among 
patients with atrial fibrillation." Journal of the American Heart Association 5.2 (2016): e003074. 
https://www.optum360coding.com/upload/docs/ingenix-insider-may-2010-stroke-and-tia.pdf 
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Woodfield, Rebecca, Ian Grant, and Cathie LM Sudlow. "Accuracy of Electronic Health Record Data for 
Identifying Stroke Cases in Large-Scale Epidemiological Studies: A Systematic Review from the UK 
Biobank Stroke Outcomes Group." PloS one 10.10 (2015): e0140533. 
Seeger, J. D., et al. "Safety and effectiveness of dabigatran and warfarin in routine care of patients with 
atrial fibrillation." Thrombosis and haemostasis114.6 (2015): 1277-1289. 
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Appendix II: Table 2 Variable Information  
 
 
  
Variable  Type Coding 
Charlson’s Comorbidity 
Index  
Categorical   0=CCI score 0 
1=CCI score 1-2 
2=CCI score 3 or more 
CHASD2SVASC Score  Categorical   1=low risk (1-2)  
2=mod-high risk (>2) 
Region  Categorical  STATES CT,ME,MA,NH,RI,VT,NJ,NY,PA = Northeast  
IN,IL,MI,OH,WI,IA,KS,MN,MO,NE,ND,SD = Midwest 
DE,DC,FL,GA,MD,NC,SC,VA,WV,AL,TN,KY,MS,AR,
LA,OK,TX = South 
AZ,CO,ID,NM,MT,UT,WY,NV,AK,CA,HI,OR,WA = 
West  
Insurance Type  Categorical   EPO=1 
 HMO=2 
 IND=3 
 OTH=4 
 POS=5 
 PPO=6 
Age  Continuous NA  
Beta blocker Use  
ARB Use  
Statin Use  
Ace Inhibitor Use  
 
Categorical 1= Yes  
0=No  
Gender  Categorical 1 =Male, 0 =Female  
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Appendix II: Table 3 Cox Models for Outcomes at Different Time-points 
 
cox model without 
covariates.rtf  
 
Appendix II: Table 4 Poisson and Negative Binomial Models for Outcomes at Different Time-points 
 
Negbin and 
Possion without cov 
 
Appendix II: KM graphs for events by adherence  
KM.docx
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ABSTRACT 
Introduction: Novel Oral Anti-coagulants (NOACs including Dabigatran and 
Rivaroxaban) are new promising drugs which have shown better or similar efficacy to 
lower stroke risk and fewer side effects compared to warfarin in the clinical trials.  In 
recent studies, Dabigatran and Rivaroxaban have demonstrated to have lower costs than 
warfarin. Although the estimates are based on numerous simulated economic modeling 
studies and meta-analysis, there is limited evidence in real world data to explain the 
distribution of cost and healthcare resource utilization (HCRU) for outcomes in NOACs.  
This study examined the adjusted AF-related costs (NOAC vs. warfarin) along with its 
sub-components (inpatient, outpatient, and drug costs) and HCRU. Additionally, bleeding 
related unadjusted cost was also calculated. Costs were further investigated for subgroups 
based on age, region, insurance type gender, CHA2DS2VASc, CCI. Moreover, a possible 
relationship between adherence to medication and HCRU/cost was also explored.  The 
evidence is critical as the NOACs move towards competing against warfarin (generic) as 
an anticoagulant.  
Methods: A retrospective cohort study was conducted utilizing data from the Optum® 
Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) database between January 
1, 2010 and December 31, 2012. The study population was identified based on 
documentation of ≥ 1 diagnosis of atrial fibrillation or flutter ICD-9 code 427.31/32, ≥ 2 
prescriptions of NOAC or warfarin, age ≥18 years and CHA2DS2VASC score ≥1.  The 
index date was the first prescription claim for NOAC or warfarin.  The adjusted HCRU 
and costs were calculated at 6 months, annually, as well as by per patient per month using 
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GLM models (gamma distribution) and compared between NOAC and warfarin cohorts.  
As an exploratory analysis, the HCRU and costs were compared across adherent (>80% 
PDC) and non-adherent NOAC patients.  
Result: Annual drug cost was higher for NOAC users ($4988 vs. $331) was offset by 
higher medical costs for warfarin users (Total annual cost for warfarin $31,400 vs. 
$22,134). The mean annual ER visits (14 vs. 13) and office visits (76 vs. 49) for warfarin 
users was slightly higher compared to NOAC users.  
Highest cost drivers for drug cost for warfarin users was patients from Northeast. 
Conversely, highest cost drivers for medical cost were patients less than <65 years and 
patients with CCI +3.  
For NOACs, the highest cost driver for the drugs was user who were 65 and above, from 
Northeast, CHA2DS2VASC >2 (mod-high risk), and independent insurance. Additionally, 
medical cost was driven by EPO insurance and CCI+3.  
Although ER visits (13.78 vs. 14.47), and inpatient costs ($20,756 vs. $23,208) were 
lower among the adherent patients, there was no significant difference in estimates 
between adherence and non-adherent patients.      
Conclusion: Although drug cost was higher among NOAC users, the total cost was offset 
by higher cost for warfarin users in inpatient and outpatient setting.  The costs presented 
by subgroups can help to target specific patient groups (higher CCI index, high stroke 
risk, patients from the Northeast, POS insurance) for greater cost savings. Adherence to 
NOACs is slightly helpful to reduce costs and HCRU but might not lead to substantial 
monetary benefits to the patient and the provider.  
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BACKGROUND 
Atrial Fibrillation (AF) is a common condition causing cardiac rhythm disturbance due to 
electrophysical or structural abnormality resulting in abnormal impulse formation.1  AF is 
one of the key risk factors for ischemic stroke, increasing the risk up to 5-fold2.  In 2010, 
the prevalence of AF in the United States (US) was 2.7 to 6.1 million and is expected to 
grow between 5.6 and 12 million in 2050.3   In the US, AF accounts for a total of 
>467,000 hospitalizations annually and leads to >99,000 deaths per year.  AF is also 
responsible for adding an amount of $26 billion to the US healthcare spending annually, 
which is mostly driven by the inpatient and outpatient costs.1    
 
Use of NOACs in AF 
Treatment options for AF primarily include antiplatelet, anticoagulant, beta blockers, 
calcium channel blockers, sodium and potassium channel blockers.4 Anticoagulants 
significantly decrease symptoms and health outcomes leading to significant patient 
benefits.5 Warfarin is an oral vitamin K-antagonist approved in 1954 and has been a gold 
standard of care for more than 50 years. The variable dosing, frequent dose adjustments 
and narrow window for therapeutic use in warfarin have prevented its the widespread 
utilization in patients. Moreover, interactions with concomitant medications, change in 
the diet, and the need for periodic monitoring has made warfarin use challenging for the 
clinicians and patients.6 
NOACs include newly approved oral drugs: dabigatran “Pradaxa” (2010), rivaroxaban 
“Xarelto” (2011), apaxiban and edoxaban. Overall, NOACs have shown better or similar 
efficacy compared to warfarin in the clinical trials.  Few benefits of NOACs include: 
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quick time-to-peak effects, fixed dosing regimens, require little monitoring, and have a 
fewer drug to drug interactions.  Although an antidote is now available for dabigatran and 
its copays have been lowered since the launch of the drug, the total cost of the branded 
NOACs compared to the generic warfarin is very high.  The challenge for the policy 
decision makers and drug reimbursement is to weigh if the high drug costs for NOAC’s 
offsets the other related medical costs, outcomes and quality of life.  
NOACs and Healthcare costs  
NOACs have been widely prescribed and covered by the insurance providers and 
Medicare Part D although the copays may vary from $30-$120.7   According to a claims 
database study by Desai et.al on 6893 patients, NOACs accounted for 62% of new 
prescriptions and 98% of anticoagulant-related drug costs in 2014.8  In some cases, on the 
formulary, NOACs may require prior authorization (if less expensive drugs might work 
better), and be used as “Step therapy” to start with the drug after generic alternative.  
Most of the providers have placed NOACs as Tier 2 (drugs are designated preferred 
brand because they have been proven to be effective, be safe, and favorably priced 
compared to other brand drugs) or 3 (have the highest copay or coinsurance, generally 
not found cost-effective).  But it is important to consider that a significant share of the 
healthcare cost comes from inpatient and outpatient setting and is crucial to guide 
decision makers in regards to the right treatment selection. 
There are some data published on the Healthcare Resource Utilization (HCRU) and 
economic outcomes of NOACs as a therapy.  In the RELY trial, the hospitalizations for 
dabigatran were lower compared to warfarin (2311 vs. 2458, p <0.003).9  A study 
comparing the HCRU between rivaroxaban and warfarin using a Humana claims 
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database reported fewer hospitalizations in rivaroxaban users compared to warfarin (AF-
related, 2.11 vs. 3.02 days; all-cause, 2.71 vs. 3.87 days).10    
Furthermore, using the same database, the healthcare costs were comparable to warfarin 
with mean hospitalization costs for rivaroxaban slightly lower than warfarin (all-cause: 
$5411 vs. $7427), although pharmacy costs were slightly higher for rivaroxaban $5316 
vs. $2620 but were not significantly different.11  For a study based on the HealthCore 
data, pharmacy costs per month for dabigatran were higher than the warfarin cohort 
$455(SD,429) vs. $328(SD, 517) but medical costs were comparable $2,696 (SD, 6,699) 
vs. $2,893 (SD, 6,819). There was no difference in the adjusted total healthcare costs 
between the two cohorts (dabigatran vs. warfarin: $2949 vs. $2959)12.  In an economic 
analysis by Deitelzweig et.al. 2012 using 10,000 Monte-Carlo iterations, it was 
demonstrated that 92.6% of the time, the one-year medical cost for dabigatran was less 
than warfarin. Similarly, 79.8% of the time, the one-year medical cost for rivaroxaban 
was less than warfarin.  The study also examined one-year medical costs of major 
bleedings (excluding hemorrhagic stroke) with dabigatran and rivaroxaban (+$31 and 
+$108, respectively) compared with warfarin.13  Based on the literature review of cost in 
AF patients, the total annual cost in 2013 ranged from $18,454 to $38,270 while inpatient 
cost was $7,841 to $22,582 per patient.14  Another database study by Fonseca et.al, the 
total cost of patients taking dabigatran and warfarin after propensity score matching was 
14,794 vs. $16,826.15 
Overall based on the recently published literature, the NOACs tend to demonstrate better 
or comparable economic outcomes than warfarin.   
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The real-world data regarding cost differences and events rate among NOAC treatment is 
limited.  No published study has examined the differences in cost and HCRU outcomes in 
detail across the clinical subgroups based a real-world data.  Also, comparison of the 
various component costs across adherence cohorts will help explore and generate a 
hypothesis in regards to the impact of adherence on clinical outcomes and its related 
HCRU. 
Study Rationale and Justification 
Although the cost estimates have been predicted by numerous simulated economic 
modeling studies and meta-analysis, there is limited real-world evidence to further 
explain the distribution of the costs and healthcare resource utilization for outcomes in 
NOACs.  This study examined the cost along with its sub-components (inpatient, 
outpatient, and drug cost) and HCRU across (sub-grouped by) clinical factors like age, 
gender, CHA2DS2VASc, CCI. Furthermore, possible relationship of adherence to 
inpatient costs and HCRU was explored.  This evidence is critical as the NOACs move 
towards competing against warfarin (generic) as an anticoagulant. Comparison between 
subgroups will help identify the cost drivers and recognize the difference in regards to 
costs in the real world to help generate hypothesis for in-depth analysis which can target 
specific subgroup and lead to higher cost savings.  The results regarding cost will help 
understand the landscape and the economic burden of NOACs on the healthcare system. 
Several inputs from the results can be used for detailed cost-effectiveness analysis and 
other economic modeling studies.  
The proposed study aims to test the following hypothesis  
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Hypothesis: Ho = There is no statistical difference in cost and HCRU between AF 
patients taking NOAC and warfarin.  
Other analyses focusing in the subgroups and comparison of cost and HCRU between 
adherent vs. non-adherent patients are aimed to generate a hypothesis. 
 
METHODOLOGY 
          Study Design 
This is a retrospective cohort study design to compare costs and HCRU between NOAC 
vs. warfarin patients across different subgroups. 
The study was conducted using medical and pharmacy claims data from January 1, 2010, 
to December 31, 2012, using a large-scale US managed care health plan affiliated to 
Optum® Clinformatics™ Data Mart (Optum Insight, Eden Prairie, MN) database. The 
primary outcome of the data was adjusted inpatient, outpatient, drug cost and HCRU 
(inpatient, ER and outpatient visits).   
Data source: The OPTUM database mainly includes medical claims, including inpatients 
and outpatient files and pharmacy claim data.  It contains details on dates of service, 
place of service, International Classification of Diseases, Ninth Revision, Clinical 
Modification ICD-9-CM/ICD-10 diagnosis codes, provider type, National Drug Code-
NDCs, drug quantity dispensed, days supplied, charges, deductibles, and copayments.  
The large US health plan database includes 14 million patients and 500,000 Medicare 
enrollees.  The member file constitutes the demographic data and eligibility information.  
The database comprehensively covers diverse geographical areas of US with most of its 
enrollees from the South and the Midwest.  The data access was compliant with the 
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Health Insurance Portability and Accountability Act.  To ensure the patient’s 
confidentiality, no identifiable protected health information was used or analyzed during 
the study16   The data was accessed using the server at the University of Rhode Island 
(URI) and analyzed using SAS EG 7.1.   The study was also approved by the Institutional 
Review Board at URI. 
Sampling design/procedures:   All patients between January 1, 2010, to December 31, 
2012, were identified.  Patients with warfarin, dabigatran or rivaroxaban (NOACs) were 
characterized using the NDC codes and brand name using REDBOOK. The index date 
was defined as the date of first prescription fill of the NOAC or warfarin in their 
respective drug cohort. Patients with at least two claims for the study drugs in the post-
index period were included. Patients were included based on at least one AF or atrial 
flutter diagnosis claim identified using the medical file (inpatient or outpatient) with an 
ICD-9 code of 427.31/427.32 during the pre-index period or 30 days within the index 
date. In addition to the AF patients, subjects with atrial flutter were also included since a 
large proportion of patients with atrial flutter also suffer from atrial fibrillation (overlap) 
and the recommended treatment is similar for AF and flutter in terms of prevention of 
stroke. Patients with age ≥ 18 years were included. Patients with concomitant use of 
warfarin and NOAC during the post-index assessment period were excluded. Few 
patients previously used warfarin in the pre-index period prior to starting the NOACs. 
Since, NOACs are also prescribed to fulfill the unmet need in few patients with prior 
warfarin use, to avoid exclusion of any NOAC user (and sample size considerations), the 
inclusion of these patients was based on the definition of “warfarin-naïve.” Based on the 
definition of ‘warfarin naïve’ in RELY trials, a patient was defined ‘warfarin-naïve’ if 
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there was no use of warfarin 2 months before the index date (first fill) of NOACs or if the 
NOAC was used for a duration of at least 5 or more.17   This criterion was to ensure we 
capture all NOAC users and avoid any potential bias in regards to prior warfarin therapy 
for assessment of outcomes.  Thus, the index date of these “warfarin-naïve” users was 
based on the first prescription fill of NOACs.  Data based on RELY trials has shown no 
heterogeneity between patients who have prior warfarin use (based on the above 
definition) and those with no prior warfarin therapy. Age was used as a continuous 
variable.  Furthermore, patients with CHA2DS2VASC score ≥1 (1-9) were identified 
using ICD-9 codes and included. The CHA2DS2VASC characterizes the risk of stroke 
based on a score composed of (congestive heart failure, hypertension, age >75 years, 
diabetes, prior stroke, pulmonary or vascular disease, age [65-74 years], sex [as female]).  
Please refer to Appendix Table 1 for ICD-9 codes. The patients with at least 6 months of 
pre and post index continuous eligibility with a permissible gap of 45 days were included 
in the cohort.  Patients with hyperthyroidism (ICD-9 242.9) were excluded from the 
patient cohort since it may be the probable cause AF but is not related to cardiac 
pathways. 
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Figure 3.1: Study Design and Timeline 
 
 
 
 
 
 
 
 
 
Outcomes 
Post-index cost and HCRU was calculated. The medical cost was defined as the total cost 
of inpatient and outpatient medical services. The medical cost was also inclusive of 
professional fees and laboratory testing (e.g. prothrombin time, INR monitoring for 
warfarin).  The total healthcare cost was the sum of all medical (inpatient, outpatient) and 
drug costs. The cost measures were expressed as annual and cost-per-patient per-month 
was calculated. 
HCRU assessment consisted of inpatient visits, outpatient office visits, and ER visits.   
The cost for the years 2010-2012 was adjusted for inflation to 2016 dollars based on the 
latest consumer price index (CPI) data by the US government 
(http://www.bls.gov/data/inflation_calculator.htm).  Patients were categorized as adherent 
(>80%) and non-adherent based on PDC calculated between the index date and 3/6 
months and HCRU was evaluated over the post index 1-year follow-up period. 
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Data Analysis:   The data were analyzed using SAS EG version 7.1.  The generalized 
linear models with gamma distribution were used to obtain and compare the adjusted 
annual and monthly per-patient costs between warfarin and NOAC users.  Age, CCI, 
CHA2D2VASC, region, insurance type, gender, and cardiac medication use were used as 
covariates. The total cost along its sub-components and HCRU was compared between 
the NOAC vs. warfarin patients at a significance level of p ≤0.05. 
The univariate statistics were presented for the subgroup analysis. The mean AF-related 
and bleeding related costs (all-cause, inpatient, medical, drug) and HCRU for NOAC vs. 
warfarin users across subgroups were measured. As an exploratory analysis, unadjusted 
HCRU and costs were compared between patients who were adherent vs. non-adherent. 
   
RESULTS 
We found a total of 25,120 users of NOACs and 149,359 users of warfarin within 
the study period. A total of 14,618 NOAC and 120,607 warfarin users had 2 or more 
prescription fills. Out of 14618 NOAC patients, 4332 patients had a prior warfarin use in 
the pre-index period, and the definition of ‘warfarin naïve’ was used to screen the 
patients. Based on the definition of ‘warfarin naïve’, 1107 out of 4332 patients were 
included as NOACs. A total of 1032 patients were excluded due to an overlap 
(concomitant use of warfarin and NOACs) in the post-index period.  Based on the other 
inclusion criteria (diagnosis of atrial fibrillation in pre-index period or 30 days within the 
index date, ≥18 years, continuous enrollment for 6 months pre and post-index, and 
CHA2DS2VASc ≥1), a total number of warfarin and NOAC patients were 8130 and 4758 
respectively. 
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Based on 6 months of drug use, a total number of 3,453 NOAC users and 5596 
warfarin users were included in the analysis.  At 12 months of the assessment period 
(drug use), the study sample consisted of 5057 patients. A total of 1770 NOAC patients 
and 3287 warfarin patients met the inclusion and exclusion criteria. Figure 1 in Appendix 
III describes the cohort sample selection in detail. 
Baseline Characteristics among NOAC and Warfarin patients  
Based on the study sample of 5057 patients, the mean age of the sample was 66 years 
with more men (66.7%) than females. The majority of the patients were either from the 
South or the Midwest (65%). Most of the patients (65%) were categorized as moderate to 
high-risk of stroke based on CHA2DS2VASC score >2. Over 80% of patients in the 
cohort had a CCI above 0. For medication use, statins were the most frequently used 
drugs (50% of patients) followed by ACE-ARB inhibitors used by more than 25% of the 
sample.   
Based on the chi-square test, most of the patient characteristics were different across the 
NOACs and warfarin.  The females preferred to use NOACs compared to patients using 
warfarin (69% vs. 64%). More than 50% of NOAC users were from the South (vs. 37% 
for warfarin users). For the stroke risk based on the CHA2DS2VASC score, a higher 
proportion of warfarin users had a moderate-high risk (more severe) compared to NOAC 
users (67% vs. 60%).  Most of the patients had CCI score > 1(85%) where patients on 
warfarin therapy were slightly severe (with a higher proportion of 3+ comorbidities) 
compared to the NOAC users (48% vs. 34%). The statin use was high in both cohorts 
(>50% of the patients).  Please refer to Table 3.1 in Tables and Figures III.  
Adherence measured by PDC 
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Adherence was measured at 3, 6, 9 and 12 months post the index date. Overall, 
NOAC patients had a higher adherence (PDC ≥80%) to the treatment as compared to the 
warfarin therapy.  At 12 months of follow-up, the proportion of adherent patients using 
NOAC was 78.42% (N=1388/1770) compared to 61.88% (N=2034/3287) for warfarin 
patients. The trend for higher adherence in NOACs vs. warfarin was preserved for 3, 6, 9-
month assessment period. Table 1.2 in Tables and Figures I compare the adherence 
measured at different time points between NOAC and warfarin cohorts. The proportion 
of adherence among NOAC patients at 3 months was (N=2859/3453) 84.30% and 
declined over time (82.80% for 6 months and 76.45% 9 months).  Similarly, the 
proportion of adherence among warfarin users at 3 months was 77.43% (N=5224/6747) 
followed by 72.61% and 61.88% for at 6 and 9 months respectively. 
Baseline Characteristics among Adherent and Non-Adherent NOAC patients 
          Based on the 12-months drug usage, the patient demographic and clinical 
characteristics were summarized for 1388 adherent and 382 non-adherent patients at 
baseline (index date).  Age, CHA2DS2VASC score, type of insurance, monthly drug costs 
and use of statins were different across the adherent and non-adherent patients. The mean 
age of patients was 65 years with adherent (66 years) patients being older than the non-
adherent (62 years) patients. The cohorts consisted of more men (69.3%) than women 
(30.7%). The majority of patients were from the South (51.3%) or the Midwest (21.9%), 
and more than 60% of the final cohort received point-of-service (POS) insurance.  
There were 39.4% patients with a CHA2DS2VASC score of 1-2 and 38.8% with a 
CHA2DS2VASC score > 2 (termed as moderate risk). Patients with moderate-high risk of 
stroke (based on the CHA2DS2VASC score) were more adherent compared to the low-
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risk patients. The CCI scores were well distributed across adherent and non-adherent 
patients.  In regards to the cardiac medication use, statin and beta-blocker use was higher 
among adherent patients compared to the non-adherent patients. Table 3.3 in Appendix 
III describes the patient demographic and clinical characteristics in detail among adherent 
and non-adherent NOAC patients. 
Comparison of Annual and Monthly All-cause AF related Healthcare (Drug cost, 
Inpatient, Outpatient and total) Costs [NOAC vs. Warfarin cohort]  
The annual AF related all-cause healthcare costs (inpatient, medical, total) were 
calculated based on the GLM model using the gamma distribution since we expected a 
skewed distribution of the cost and the gamma model being acceptable approach handling 
the cost data.18   
As expected, the annual drug cost for warfarin users was significantly lower compared to 
the NOAC users (331 vs. 4988) since the NOACs are branded drugs and warfarin is 
generic on the market. However, the medical cost which included all inpatient and 
outpatient costs were significantly higher ($31,400 vs. $22,134) for patients on warfarin 
therapy as compared to the NOAC users. The individual inpatient cost for warfarin users 
was $25,405 compared $15,362 for patients taking NOACs. 
The total healthcare cost consists of the sum of all drug cost (including copays and 
deductibles), inpatient cost, outpatient cost (including the professional fees, and cost of 
INR monitoring specifically for the warfarin users). The total annual adjusted AF-related 
cost for warfarin users was significantly higher than NOAC users ($32,157 vs. $26,803).  
Overall, the high drug cost for NOAC users was offset by higher inpatient and outpatient 
costs (medical costs) for warfarin users.  
 106 
 
A similar trend was observed for the monthly all-cause total cost (+ $388) and medical 
costs (+ $773) significantly greater for warfarin users compared to the NOAC users.  
Please refer to Table 3.4 and 3.5 in Appendix III for detailed results.  
Comparison of Healthcare Resource Utilization (NOAC vs. Warfarin cohort)  
The adjusted estimates for annual ER visits for warfarin were similar compared to NOAC 
users (14 vs. 13, p=0.4607).  Although, there was a significant difference in the number 
of annual office visits between warfarin and NOAC (76 vs. 49) users.  Similar results 
with a higher ER (1.14 vs. 1.04) and office visits (6.37 vs. 4.11) was observed for the 
monthly estimates for warfarin vs. NOAC users.  Please refer to Table 3.4 and 3.5 in 
Appendix III for detailed results. 
Subgroup Analysis  
The different components of the all-cause annual cost (including the drug, inpatients, 
medical costs) and HCRU were described across the subgroups.  Age, gender, region, 
insurance type, CHA2D2VASC, and CCI were the major subgroups.  
Comparison of Costs by Subgroups 
Drug Cost 
The drug cost was highest in the Northeast region for both warfarin and NOACs. Annual 
drug costs for the older patients was slightly higher compared to younger patients on 
NOACs (5284 vs. 5064). Patients with an independent coverage for NOACs and POS for 
warfarin had highest drug costs compared to other types of insurance (including HMO, 
PPO, EPO, and Others). As expected, the drug cost for NOACs increased with the stroke 
risk.  The patients on NOACs with moderate to high-risk CHA2D2VASC had higher drug 
cost compared to low-risk patients (5205 vs. 4941).  A similar trend of increase in drug 
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cost based on higher CCI was observed for the NOAC users. Please refer to Table 3.6 in 
Appendix III for the detailed results. 
 
Medical Cost (Inpatient and Outpatient costs)  
Annual overall medical costs for NOAC or warfarin users was higher in males, patients 
with EPO insurance, 3+ comorbidities based on CCI and patients from the South.  The 
numbers might be due higher proportion of males and patients from the South in the 
entire population. The medical cost for NOAC patients increased with severity by CCI 
($19820 for CCI=0, $26396 for CCI=1-2, and $41144 for CCI ≥3). 
On the contrary, the patients in the low-risk CHA2D2VASC group had slightly higher 
medical cost compared to the patients in the higher risk groups (36024 vs. 29247). Please 
refer to Table 3.7 in Appendix III for the detailed results. 
 
Healthcare Resource Utilization  
Annual ER visits for patients using warfarin were highest in the Midwest (16.6. For 
patients on the NOAC therapy, highest ER visits were in patients from the Northeast (18). 
The mean annual ER visits were higher in patients with age < 65 years’ in both NOAC 
(13 vs. 7) and warfarin (16 vs. 10) user cohort.  In both cohorts (warfarin and NOAC), 
ER visits were higher for patients with HMO and POS insurance. Mean annual ER visits 
were not significantly different across clinical severity based subgroups (CHA2D2VASC 
and CCI).  Please refer to Table 3.8 in Appendix III for the detailed results. 
Mean annual office visits were higher in females in both NOAC (52 vs. 46) and warfarin 
(79 vs. 74) user cohorts. Similarly, the office visits were higher among patients with 
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moderate to high stroke risk and for more severe patients with 3+ co-morbidities based on 
CCI in both NOAC and warfarin users. For NOAC patients, the office visit for mild vs. 
moderate-severe CHA2D2VASC score was 37 vs. 50 respectively.  The NOAC users with 
Independent (Annual office visits 55) and PPO (Annual Office visits - 56) insurance had 
a higher number of office visits compared to other insurance types. Please refer to Table 
3.9 and 3.10 in Appendix III for detail on HCRU by subgroups.  
 
Overall Results 
Highest cost drivers for drug cost for warfarin users was patients from Northeast. 
Conversely, highest cost drivers for medical cost were patients less than <65 years and 
patients with CCI +3.  
For NOACs, the highest cost driver for the drugs was user who were 65 and above, from 
Northeast, CHA2DS2VASC >2 (mod-high risk), and independent insurance. Additionally, 
medical cost was driven by EPO insurance and CCI+3.  
Although ER visits (13.78 vs. 14.47), and inpatient costs ($20,756 vs. $23,208) were 
lower among the adherent patients, there was no significant difference in estimates 
between adherence and non-adherent patients.     
 
Bleeding Related Costs  
A total of 558 and 224 patients had bleeding related costs. Annual bleeding related drug 
cost was significantly higher for NOACs compared to warfarin ($6057 vs $3737).  This 
trend was also consistent for monthly drug costs for NOACs vs Warfarin ($505 vs $311).  
Please refer to Table 3.14 in Appendix III for detail on HCRU by subgroups.  
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Similar to all cause AF related costs, the bleeding related medical cost for NOACs was 
lower ($1741 vs $6021) compared to warfarin.   
The main cost drivers for bleeding related medical costs for warfarin were patients with 
Age <65 and patients with EPO insurance while the main drivers for NOACs users were 
higher CCI and EPO insurance. Please refer to Table 3.12 and 3.13 in Appendix III for 
detail on HCRU by subgroups.  
 
Comparison of Annual HCRU and Costs by Adherence 
As an exploratory analysis to generate a possible hypothesis, cost and HCRU were 
compared across adherent and non-adherent cohorts for NOAC users. The HCRU was 
compared between the adherent and non-adherent NOAC patients based on the 12-
months of drug use.  Although ER visits (10.59 vs. 12.68), inpatient costs ($24760 vs. 
$30549) and all-cause total cost ($34854 vs. $37821) was lower among the adherent 
patients, there was no significant difference between the estimates for adherence and non-
adherent patients. Conversely, adherent patients had non-significantly higher office visits 
compared to the non-adherent patients. Please refer to Table 3.11 in Appendix III. 
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DISCUSSION 
Our study found the economic burden of atrial fibrillation on anticoagulant users based 
on total annual healthcare cost was substantial (>$25,000).  Moreover, the total annual 
healthcare costs for warfarin users was higher compared to the patients taking NOACs. 
The inpatient and outpatient costs for NOAC users were significantly lower compared to 
patients with warfarin therapy, which offset the higher drug costs for NOACs.  Moreover, 
warfarin patients had higher ER and office visits (HCRU) compared to NOAC patients.  
Approximately, at least 60% of the total cost was attributed to the inpatient setting. 
Our study was the first to investigate each of the cost (Medical, inpatient) and HCRU (ER 
and office visits) components among NOAC vs. warfarin users across clinically 
important subgroups.  The results provided valuable insights to identify specific patient 
groups with high cost and HCRU and can help to plan targeted approaches and 
interventions. Also, the real world cost estimates can be used as cost input in further 
budget impact and cost-effectiveness studies. 
Our study was also the first to explore an impact of medication adherence on cost and 
HCRU in AF patients.  Although our study did not find any association of adherence with 
a decrease in cost, it indicates that increase in adherence does not lead to any additional 
use of economic resources. Further in-depth analysis using matched cohorts is warranted.  
Our estimates of the healthcare costs (drug, medical, total) were consistent with the 
existing literature. Based on United States Department of Defense (DOD) Military Health 
System data, drug costs were higher ($4369, p < 0.001) for dabigatran compared to 
warfarin which is similar to our estimated drug costs.19  Mercaldi et.al. compared an 
annual healthcare cost between patients without a major event ($15,718 in 2006 US 
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dollars) vs. patients who had an ischemic stroke, hemorrhagic stroke, or major bleeding 
($43,937; $60,123; and $39,943 respectively).20 Based on the MarketScan data (2003-
2007), unadjusted all-cause health care costs in the 12 months after the warfarin index 
claim were $41,903 ($56,654), $40,586 ($65,164), and $24,347 ($56,488) for patients 
with at least 1 ICH, major GI bleeding, and minor GI bleeding, respectively, compared 
with $24,129 ($36,425) for subjects with no bleeding episodes.21  Based on a combined 
data using two large administrative databases (Optum and Medicare), the total AF-related 
healthcare cost for patients aged 18 to 64 years was $38,861 (95% CI $35,781- 
$41,950).22  Furthermore, a comprehensive review of the literature (PubMed and Medline 
search) resulted in total healthcare cost for AF from $18,454 to $38,270.14  Although, it 
should be acknowledged that cost estimates reported in our analyses are adjusted using a 
multivariate model. In another study based on the Medicare beneficiaries, the healthcare 
costs for patients with ischemic stroke were $63,781 per patient and $64,596 for patients 
with hemorrhage versus $35,474 for patients without these events.23   Higher drug cost 
for the NOACs can be explained by the fact that dabigatran and rivaroxaban are branded 
medications with higher co-pays.  Lower inpatients and outpatient cost for NOACs can 
be attributed to a lower propensity of risk outcomes (strokes, recurrent DVTPE, bleeding, 
PE, etc.) in patients taking NOACs. 
A study based on the claims data 2010-2011 reported, patients on dabigatran had fewer 
per-month ER visits (0.10 vs. 0.13, P = 0.010), and office visits (1.98 vs. 2.96, P < 0.001) 
compared to the patients on warfarin therapy.24    Furthermore, in a study based on the 
Medicare data, the total outpatient visits for a 12-month period were 53.25 
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Our study found higher estimates which might be attributed to the inclusion of a higher 
proportion of patients with moderate to high-risk of stroke and CCI index of +3.  Higher 
ER and office visits in warfarin might be due to the suboptimal utilization of INR testing 
lead to complications in regards to inadequate anticoagulation.  
A study on warfarin users found no significant differences in costs and HCRU between 
adherent and non-adherent patients.26  Based on our results, the above inference relates to 
the entire class of anticoagulants including the NOACs. 
Our study was the first to compare the HCRU and cost between the NOAC and warfarin 
taking patients and to quantify the estimates across the demographic and clinical 
subgroups.  The Northeast region had highest drug costs, which could be due to better 
healthcare and insurance availability (coverage) in the region.  Annual overall medical 
costs for NOAC or warfarin patients was higher for patients with 3+ comorbidities based 
on CCI, and for patients from the South.  Our study found higher cost was associated 
with lower age (<65) which is consistent with previous cost studies in AF.22,27  It is 
important to note that younger patients might be aggressively treated than older patients 
for AF. 
Our study identified higher burden of cost and resource utilization is incurred on specific 
subgroup of the patients taking NOACs e.g. total cost and ER visits were higher in males. 
The drug cost, inpatient costs, and HCRU were highest for patients in the Northeast 
region. The medical cost and HCRU were highest for the patients with POS insurance. 
Higher stroke risk and CCI score in NOAC users translated into higher costs and HCRU.  
These results provide valuable insight on the utilization of healthcare resources in regards 
to targeting specific population groups.   
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One of the advantages of the study was the use of large commercial database represented 
by population across the United States. All the cost reported were adjusted to 2016 
according to the latest consumer price index (CPI) data released by US government. It 
should be considered that even though generic warfarin is cheaper than warfarin, the cost 
of regular INR monitoring is an additional cost for the warfarin users. Our study found a 
total of 2464 patients (74%) who checked their INR and had an average cost of $120 per 
person per year. We also included INR monitoring costs for calculating the total 
healthcare costs.  The healthcare costs, including the inpatient, medical, and total cost 
were adjusted using the gamma model; the crude confidence intervals were obtained by 
exponentiating the estimates.  
The aim of the subgroup analysis and comparison of adherence based cohorts was 
targeted at hypothesis generation, and thus, any disease specific (GI related, stroke 
related) costs were not examined.  All-cause costs were estimated to understand the 
landscape and economic burden in the AF-related population. The estimates for drug 
cost, HCRU, and medical costs can be applied to the economic models, while the 
estimates based on the comparison between adherent and non-adherent samples can be 
helpful for meta-analyses and indirect comparisons. Further studies can be planned in 
regards to event-specific estimates (related to stroke, bleeding, DVTPE) and cost-
effectiveness analysis.  
It should be noted that the costs estimated in our subgroup analysis were not adjusted.  
Although cost estimates (inpatient, medical, total cost) were adjusted using GLM models, 
there was no matching performed on NOAC vs. warfarin cohort, so there might be a 
possibility of selection bias due to unmeasured factors in regards to the sample 
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populations.  Use of a large administrative database may not be generalizable as it is 
mostly represented by commercially insured population. Furthermore, use of claims data 
may lead to reliance on diagnosis, coding and lack of clinical details. In our cohort with 
12 months of follow-up assessment, most of the drug prescriptions were accounted for 
the years 2010-2011 (2010 – Warfarin – 1438, NOAC-178 and 2011 warfarin – 1829, 
NOAC=1583), with very few patients in 2012 due to criteria for a follow-up of 12 
months. Hence, further analysis with longer follow-up time may help to capture details 
and specific patterns. 
Accepting these limitations, our results can be used to help support reimbursement 
decisions and help generate hypothesis for more comprehensive studies. Inputs can be 
helpful in the further economic analysis and meta-analyses.   
CONCLUSION 
The study helps to estimate the substantial economic burden of AF in warfarin and 
NOAC users. The higher drug cost of NOACs was offset by the lower inpatient and 
outpatient costs and HCRU for the NOAC users as compared to warfarin users. There is 
no significant difference in costs and HCRU (except office visits) between adherent and 
non-adherent NOAC patients. The study provides valuable insight, identifying specific 
subgroups (e.g. Patients from the Northeast/South, less than 65, HMO/POS and a higher 
severity based on CHA2D2VASC and CCI) with a higher burden of cost and resource 
utilization in warfarin and NOAC users.  These results could help the decision makers to 
balance the risk over benefit, and consider the cost associated with an optimal therapeutic 
choice of anticoagulants. Further research on the use of NOACs in regards to the specific 
outcomes and its cost-effectiveness is warranted.   
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TABLES AND FIGURES III 
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Figure 3.1 Study Cohort 
 
Patients with ≥2 fills in post index period 
NOAC = (N=14618) and Warfarin (N=120607)  
Adult patients Age ≥ 18  
NOAC (N=10345) and Warfarin (N=114230) 
 
Continuous enrollment for 6 months’ pre-index and 6 months’ post 
index (45 Day gap)   
Warfarin (N=29269), NOAC (N=5790) 
 
NOAC  
3 Months Drug Use (N=4070) 
6 Months Drug Use (N=3453) 
9 Months Drug Use (N=2539) 
12 Months Drug Use (N=1770) 
 
Warfarin  
3 Months Drug Use (N=6747) 
6 Months Drug Use (N=5596) 
9 Months Drug Use (N=4326) 
12 Months Drug Use (N=3287) 
Exclude Patients with ≤1fills  
Adult patients with any NOAC Drug Use (N=25,120) 
Warfarin N = (149395) 
1. if warfarin is used before 
NOAC: if a patient has warfarin 
prescription < 60 days or gap 
between warfarin and NOAC is 
5 months or greater; then the 
patient is termed as warfarin 
naive 
2. if warfarin use with or after 
NOAC; then patient is 
excluded (out of 14618 NOAC 
patients, 4332 where warfarin 
was used prior to NOAC in the 
pre-index period and the 
definition of warfarin naïve was 
used. Based on warfarin naïve 
definition 1107 patients were 
included as NOACs, 1032 were 
excluded due to overlap in the 
post index period) 
Diagnosis of Atrial Fibrillation (427.31) or Flutter (427.32) in pre-index or 
within 30days of index date; Warfarin (N=8834) NOAC (N=5164) 
CHA2DS2VASc ≥ 1;  
Warfarin (N=8130) NOAC (N=4758) 
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Table 3.1 Patient Demographic and Clinical Characteristic of NOAC vs Warfarin patients at 12-month assessment 
period 
Variable Description 
Statistic 
Response 
Category 
Total 
 (N= 5,057) 
NOACs  
(N= 1,770) 
Warfarin 
 (N= 3,287) 
P-value 
(Chi-sq) 
Age at index date  N 5057 1,770 3,287 <0.001 
 Mean (SD) 65.94 (11.61) 65.2 (10.56) 66.34 (12.13)  
 Median(IQR) 64 (58-75) 64 (59,73) 65 (58,76)  
 Range 18-86 26,86 18,86  
Gender Female 1,718 (33.97) 544 (30.73) 1,174 (35.72) 0.0004 
 Male 3,339 (66.03) 1,226 (69.27) 2,113 (64.28)  
Insurance type EPO 512 (10.12) 204 (11.53) 308 (9.37)  
 HMO 312 (6.17) 103 (5.82) 209 (6.36)  
 IND 1,030 (20.37) 280 (15.82) 750 (22.82)  
 Others 7 (0.14) 0 (0.00) 7 (0.21)  
 POS 2,945 (58.24) 1,104 (62.37) 1,841 (56.01)  
 PPO 251 (4.96) 79 (4.46) 172 (5.23)  
Region Midwest 1,469 (29.05) 388 (21.92) 1,081 (32.89) <0.001 
 Northeast 534 (10.56) 168 (9.49) 366 (11.13)  
 South 2,134 (42.20) 908 (51.30) 1,226 (37.30)  
 West 920 (18.19) 306 (17.29) 614 (18.68)  
Stroke risk (CHA2D2VASC) low risk 1,762 (34.84) 697 (39.38) 1,065 (32.40) <0.001 
 mod-high risk 3,295 (65.16) 1,073 (60.62) 2,222 (67.60)  
CCI category CCI score 0 715 (14.14) 311 (17.57) 404 (12.29) <0.001. 
 CCI score 1-2 2,140 (42.32) 851 (48.08) 1,289 (39.22)  
 CCI score 3 and+ 2,202 (43.54) 608 (34.35) 1,594 (48.49)  
Statin use Yes 2478(49.0) 917(51.81) 1561 (47.49) 0.003 
 No 2579 (51.0) 853 (48.19) 1726 (52.51)  
ACE ARB Inhibitor Yes 2382 (47.10) 874 (49.38) 1508 (45.88) 0.017 
 No 2675 (52.90) 896 (50.62) 1779 (54.12)  
Beta-blocker  Yes 1392 (27.53) 536(30.28) 856 (26.04) 0.001 
 No 3665 (72.47) 1234 (69.72) 2431(73.93)  
CCI- Charlson’s comorbidity Index, HMO – Health maintenance organization, PPO- Preferred provider 
organization, EPO -  Exclusive provider organizations, IND- Independent, POS-Point of service, ARB- 
Angiotensin Receptor Blocker, ACE- Angiotensin-converting enzyme 
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Table 3.2 Adherence Measured by PDC at Different Time-points 
Adherence  N Adherence  
NOACs 
N Adherence  
Warfarin 
p-value 
      
6 months  3453 2859 (82.80%) 5596 4063 (72.61%) <0.001 
12 months  1770 1388 (78.42%) 3287 2034 (61.88%) <0.001 
 
*PDC ≥ 80 = Adherent, Adherence measured by PDC at different time points  
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Table 3.3 Patient Demographic and Clinical Characteristics of Adherent Vs Non-adherent NOAC patients 
at 12-month Assessment Period 
 
Variable Description 
Statistic 
Response 
Category 
Total 
(N= 1,770) 
Adherent 
 (N= 1,388) 
Non-Adherent 
 (N= 382) 
 
p-value 
Age at index date N 1770 1,388 382 <.0001 
 Mean (SD) 65.20 (10.55) 66.02 (10.16) 62.24 (11.42)  
 Median(IQR) 64 (59, 73) 64 (59,73) 62 (55,68)  
 Range 26,83 34,86 26,86  
Gender Female 544 (30.73) 426 (30.69) 118 (30.89) 0.9407 
 Male 1,226 (69.27) 962 (69.31) 264 (69.11)  
Insurance type EPO 204 (11.53) 143 (10.30) 61 (15.97) <0.001 
 HMO 103 (5.82) 73 (5.26) 30 (7.85)  
 IND 280 (15.82) 239 (17.22) 41 (10.73)  
 POS 1,104 (62.37) 862 (62.10) 242 (63.35)  
 PPO 79 (4.46) 71 (5.12) 8 (2.09)  
Region Midwest 388 (21.92) 317 (22.84) 71 (18.59) 0.0487 
 Northeast 168 (9.49) 132 (9.51) 36 (9.42)  
 South 908 (51.30) 689 (49.64) 219 (57.33)  
 West 306 (17.29) 250 (18.01) 56 (14.66)  
Stroke risk 
(CHA2D2VASC) 
Low risk 697 (39.38) 515 (37.10) 182 (47.64) 0.0002 
 Mod-high risk 1073 (60.62) 873 (62.90) 200 (54.36)  
CCI Category CCI score 0 311 (17.57) 239 (17.22) 72 (18.84) 0.5734 
 CCI score 1-2 851 (48.08) 676 (48.70) 175 (45.81)  
 CCI score 3 
and+ 
608 (34.35) 473 (34.08) 135 (35.34)  
Statin Use No 853 (48.19) 636 (45.82) 217 (56.81) 0.0001 
 Yes 917 (51.81) 752 (54.18) 165 (43.19)  
ACE ARB Inhibitor Use No 896 (50.62) 688 (49.57) 208 (54.45) 0.0910 
 Yes 874 (49.38) 700 (50.43) 174 (45.55)  
Beta-blocker Use No 1,234 (69.72) 980 (70.61) 254 (66.49) 0.1213 
 Yes 536 (30.28) 408 (29.39) 128 (33.51)  
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Variable Description 
Statistic 
Response 
Category 
Total 
(N= 1,770) 
Adherent 
 (N= 1,388) 
Non-Adherent 
 (N= 382) 
 
p-value 
CCI- Charlson’s comorbidity Index, HMO – Health maintenance organization, PPO- Preferred provider 
organization, EPO -  Exclusive provider organizations, IND- Independent, POS-Point of service, ARB- Angiotensin 
Receptor Blocker, ACE- Angiotensin-converting enzyme 
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Table 3.4: Annual Cost by Type and Drug Class  
 
*The costs presented in the above tables are adjusted using GLM model using gamma distribution. The 
total cost of INR monitoring among warfarin users is $120 per year (n=2464) is calculated separately and is 
included in the total cost. 
 
 
 
 
 
  
Drug Cost Type  Average Cost* Upper 95%CI  Lower 95%CI p-value 
Warfarin  Drug Cost  $331 $361 $303 <.0001 
NOAC  $4,988 $5,464 $4,554  
Warfarin  Medical Cost  $31,400 $36,548 $26,977 <.0001 
NOAC  $22,134 $25,876 $18,933  
Warfarin  Inpatient Cost $25,405 $31,197 $20,688 <.0001 
NOAC  $15,362 $19,060 $12,381  
Warfarin  Total Cost  $32,157 $37,029 $27,925 <.0001 
NOAC  $26,803 $30,989 $23,182  
Warfarin  ER Visits 14 18 11 0.4286 
NOAC  13 17 9  
Warfarin  Office Visits 76 85 69 <.0001 
NOAC  49 55 44  
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Table 3.5: Monthly Cost by Type and Drug Class  
 
 
 
*The costs presented in the above tables are adjusted using GLM model using gamma distribution. The 
total cost of INR monitoring among warfarin users is $10 per month (n=2464) is calculated separately and 
is included in the total cost 
 
  
Drug Cost Type  Average Cost* Upper 95%CI  Lower 95%CI p-value 
Warfarin  Drug Cost  $28 $30 $25 <.0001 
NOAC  $416 $455 $379  
Warfarin  Medical Cost  $2,617 $3,046 $2,248 <.0001 
NOAC  $1,844 $2,156 $1,578  
Warfarin  Inpatient Cost $2,117 $2,600 $1,724 <.0001 
NOAC  $1,280 $1,588 $1,032  
Warfarin  Total Cost  $2,680 $3,086 $2,327 <.0001 
NOAC  $2,234 $2,582 $1,932  
Warfarin  ER Visits 1.14 1.49 0.87 0.4286 
NOAC  1.04 1.43 0.76  
Warfarin  Office Visits 6.37 7.07 5.74 <.0001 
NOAC  4.11 4.58 3.69  
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Table 3.6 Annual Drug Cost by Subgroup and Drug Class 
Subgroup  Drug Class Category 
N 
Obs N Mean Std Dev Median Minimum 
Maximu
m 
 
Warfarin 
Female 1174 1168 354.04 312.83 278.46 4.11 3148.81 
Gender Male 2113 2104 340.91 281.59 283.69 9.11 3552.00 
 
NOAC 
Female 544 543 5078.49 1847.40 5179.27 273.70 10555.10 
 
Male 1226 1221 5201.73 1847.40 5323.20 273.70 12028.14 
 
Warfarin 
Northeast 366 361 388.02 328.98 311.98 16.45 2277.69 
 
Midwest 1081 1081 337.66 280.87 282.13 4.11 3552.00 
Region South 1226 1220 355.60 308.29 284.82 9.11 2938.84 
 
West 614 610 314.57 255.14 259.20 9.88 2909.16 
 
NOAC 
Northeast 168 168 5277.96 1905.65 5489.09 273.70 9032.22 
 
Midwest 388 387 5160.54 1796.92 5259.27 273.70 12028.14 
 
South 908 904 5117.97 1817.63 5198.69 273.70 9786.22 
 
West 306 305 5240.89 1967.81 5384.12 274.54 10555.10 
 
Warfarin 
Less than 
65 1621 1619 363.76 317.27 296.19 9.11 3552.00 
Age 
65 and 
above 1666 1653 327.81 266.31 266.08 4.11 2909.16 
 
NOAC 
Less than 
65 967 966 5064.21 1856.19 5155.56 273.70 10179.17 
 
65 and 
above 803 798 5284.35 1831.41 5467.06 273.70 12028.14 
 
Warfarin 
EPO 308 307 352.87 277.36 289.91 14.69 2219.53 
 
HMO 209 209 348.77 288.05 291.47 10.42 2192.64 
Insurance IND 750 743 311.74 265.97 242.79 12.48 2909.16 
 
OTH 7 7 285.46 116.89 338.27 52.77 401.94 
 
POS 1841 1840 359.33 305.98 290.92 4.11 3552.00 
 
PPO 172 166 330.07 293.99 294.81 9.88 2800.44 
 
NOAC 
EPO 204 204 5012.03 1999.75 5162.89 313.70 9073.53 
 
HMO 103 103 4913.11 2015.80 5030.56 333.70 9231.90 
 
IND 280 278 5446.05 1901.29 5564.18 273.70 12028.14 
 
POS 1104 1103 5142.91 1772.55 5179.27 273.70 10179.17 
 
PPO 79 76 5181.57 1984.58 5455.72 273.70 9032.22 
 
Warfarin Low risk 436 435 388.35 365.95 299.07 12.22 2800.44 
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Chads2 
Mod-high 
risk 2851 2837 339.04 279.81 278.26 4.11 3552.00 
 NOAC 
Low risk 278 278 4941.17 1863.25 5060.59 313.70 9576.13 
 
Mod-high 
risk 1492 1486 5205.45 1842.48 5339.76 273.70 12028.14 
 Warfarin 
CCI score 
0 404 404 361.20 377.90 270.87 14.79 3552.00 
CCI 
CCI score 
1-2 1289 1284 338.73 270.59 287.06 9.11 2800.44 
 
CCI score 
3 and+ 1594 1584 347.19 285.95 280.75 4.11 2938.84 
 
NOAC 
CCI score 
0 311 310 5014.82 1962.94 5186.12 273.70 10179.17 
 
CCI score 
1-2 851 848 5200.81 1827.30 5267.87 273.70 10555.10 
 
CCI score 
3 and+ 608 606 5188.22 1814.55 5339.27 274.54 12028.14 
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Table 3.7 Annual Medical Cost (Inpatient + Outpatient) by Subgroup and Drug Class 
Subgroup  Drug Class Gender 
N 
Obs N Mean Std Dev Median Min Maximum 
 
Warfarin 
Female 1174 1174 47168.99 89846.58 21340.52 215.93 1147512.98 
Gender Male 2111 2111 55250.38 126739.3 21003.33 20.91 2081065.33 
 
NOAC Female 544 544 29140.59 38510.35 15955.13 160.94 392835.74 
 
  Male 1225 1225 30833.15 61775.08 14701.66 232.99 1652255.80 
 
Warfarin 
Northeast 366 366 43149.24 67505.72 21221.89 1038.5 810134.03 
 
Midwest 1080 1080 45867.41 94433.27 20044.85 336.36 1271323.63 
Region South 1225 1225 58866.35 128163.8 23370.72 20.91 2081065.33 
 
West 614 614 56301.71 139224.1 20185.02 96.72 1842247.09 
 
NOAC Northeast 168 168 29891.14 44790.03 16746.95 301.67 392835.74 
 
  Midwest 387 387 28238.03 36556.32 15792.93 231.00 347369.24 
 
  South 908 908 31988.93 66846.50 15491.25 160.94 1652255.80 
 
  West 306 306 28193.82 43153.67 13043.94 239.36 400422.86 
 
Warfarin 
Less than 
65 1620 1620 66859.90 148070.8 23318.95 20.91 2081065.33 
Age 
65 and 
above 1665 1665 38256.40 65973.35 20156.99 96.72 919247.71 
 
NOAC 
Less than 
65 967 967 34682.07 68665.02 16249.84 160.94 1652255.80 
 
65 and 
above 802 802 25044.30 33184.19 13816.1 231.00 434644.18 
 
Warfarin 
EPO 308 308 63486.28 151724.61 24402.41 1581.57 1842247.09 
 
HMO 209 209 64412.09 127540.03 17072.87 791.48 998725.56 
Region IND 750 750 33043.61 56963.08 19703.58 309.05 1082104.45 
 
OTH 7 7 18523.34 19706.42 13936.98 2367.18 56630.46 
 
POS 1840 1840 58275.45 126602.58 22022.87 20.91 2081065.33 
 
PPO 171 171 40086.85 59660.44 20604.25 215.93 525007.47 
 
NOAC 
EPO 204 204 41627.80 121491.17 14373.22 287.06 1652255.80 
 
HMO 103 103 27131.50 30526.27 13706.97 360.88 158301.04 
 
IND 280 280 22299.83 23890.75 14345.6 488.40 154088.76 
 
POS 1103 1103 31034.30 43772.63 15888.65 160.94 434644.18 
 
PPO 79 79 23565.72 29082.37 11068.98 1224.9 154167.08 
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 Warfarin 
Low risk 435 435 47065.99 124622.72 17772.68 20.91 2081065.33 
Chads2 
Mod-high 
risk 2850 2850 53170.61 113430.16 21630.34 96.72 1842247.09 
 NOAC 
Low risk 278 278 36024.49 106001.65 14074.62 160.94 1652255.80 
 
Mod-high 
risk 1491 1491 29247.67 39748.58 15477.46 231.00 434644.18 
 Warfarin 
CCI score 
0 402 402 19878.22 30131.87 10061.59 96.72 274525.38 
CCI 
CCI score 
1-2 1289 1289 33107.30 74092.66 16511.74 20.91 2081065.33 
 
CCI score 
3 and+ 1594 1594 76125.22 146466.61 32284.13 215.93 1842247.09 
 
NOAC 
CCI score 
0 310 310 19819.83 27390.49 9696.85 160.94 179454.06 
 
CCI score 
1-2 851 851 26396.24 37887.51 13151.84 231.00 434644.18 
 
CCI score 
3 and+ 608 608 41144.31 80226.92 22435.48 301.67 1652255.80 
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Table 3.8. Annual Inpatient Cost by Subgroup and Drug Classes  
Subgroup  Drug Class Subgroup  
N 
Obs N Mean Std Dev Median Minimum Maximum 
 
Warfarin 
Female 569 569 39942.35 79794.05 15156.45 35.18 1010478.85 
Gender Male 928 928 54957.10 135035.32 19506.5 28.06 1910471.44 
 
NOAC 
Female 189 189 23653.22 29106.53 12239.85 12.78 204592.61 
 
Male 376 376 27334.06 38633.13 12741.74 50.08 381637.34 
 
Warfarin 
Northeast 173 173 36692.14 65881.37 17069.78 106.15 753940.11 
 
Midwest 501 501 39085.00 76070.93 14812.88 35.18 715110.02 
Region South 552 552 62783.34 146125.13 22786.9 260.26 1910471.44 
 
West 271 271 48493.19 136272.44 14378.71 28.06 1807675.41 
 
NOAC 
Northeast 56 56 27776.63 33892.66 10655.19 131.87 152263.47 
 
Midwest 135 135 25853.79 30525.88 13088.99 17.31 148662.21 
 
South 275 275 27012.33 38555.11 13399.44 50.08 381637.34 
 
West 99 99 22968.91 35565.55 10153.53 12.78 204592.61 
 
Warfarin 
Less than 
65 713 713 73664.40 155664.23 30334.14 198.68 1910471.44 
Age 
65 and 
above 784 784 27046.77 56902.01 11681.34 28.06 842068.51 
 
NOAC 
Less than 
65 303 303 32673.05 42153.26 17789.68 50.08 381637.34 
 
65 and 
above 262 262 18504.32 24435.41 9373.92 12.78 148662.21 
 
Warfarin 
EPO 140 140 71822.23 184891.04 27120.22 871.24 1807675.41 
 
HMO 93 93 72514.07 119336.20 28831.58 1272.23 591538.44 
Region IND 372 372 18568.98 21972.65 11154.1 28.06 218371.22 
 
OTH 4 4 8497.43 7266.26 6720 2104.01 18445.72 
 
POS 811 811 58668.65 129980.99 21515.12 82.00 1910471.44 
 
PPO 77 77 31253.75 35900.20 15346.6 613.11 167665.10 
 
NOAC 
EPO 62 62 41956.95 63342.91 24441.25 50.08 381637.34 
 
HMO 37 37 22890.85 24711.01 11579.86 410.14 113688.69 
 
IND 103 103 14577.70 17908.27 8922.69 17.31 106211.49 
 
POS 342 342 27570.64 33554.29 13502.13 12.78 204592.61 
 
PPO 21 21 17576.78 16408.66 12376.95 3510.34 67241.71 
 
Warfarin Low risk 163 163 58787.54 168153.40 25051.38 387.14 1910471.44 
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Chads2 
Mod-high 
risk 1334 1334 48084.72 109565.61 16130.49 28.06 1807675.41 
 NOAC 
Low risk 80 80 37532.69 53030.35 20178.46 503.08 381637.34 
 
Mod-high 
risk 485 485 24217.42 31698.79 11596.29 12.78 287687.38 
 Warfarin 
CCI score 
0 81 81 22724.00 28764.43 13705.23 383.73 218371.22 
CCI 
CCI score 
1-2 440 440 36583.27 102815.09 15000.34 35.18 1910471.44 
 
CCI score 
3 and+ 976 976 57161.99 126911.72 19216.51 28.06 1807675.41 
 
NOAC 
CCI score 
0 60 60 20290.43 17632.32 12035.4 1549.40 69858.01 
 
CCI score 
1-2 232 232 23408.02 30214.18 11685.66 12.78 204592.61 
 
CCI score 
3 and+ 273 273 29670.25 42194.49 14008.55 17.31 381637.34 
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Table 3.9 . Annual ER Count by Subgroup and Drug Class 
Subgroup  Drug Class Subgroup  
N 
Obs N Mean 
Std 
Dev Median Min 
Maximu
m 
 
Warfarin Female 1174 143 14.87 21.61 5 1 109 
Gender   Male 2111 269 13.13 25.41 4 1 318 
 
NOAC 
Female 544 68 10.63 16.95 4 1 92 
 
Male 1225 143 11.24 16.98 3 1 82 
 
Warfarin Northeast 366 41 8.73 15.18 3 1 84 
 
  Midwest 1080 157 16.64 21.15 6 1 109 
Region   South 1225 145 13.13 19.93 3 1 106 
 
  West 614 69 11.36 38.47 3 1 318 
 
NOAC 
Northeast 168 10 18.00 25.12 4.5 1 75 
 
Midwest 387 49 12.80 14.84 8 1 80 
 
South 908 114 8.29 12.34 2 1 59 
 
West 306 38 15.21 25.77 3 1 92 
 Warfarin 
Less than 65 1620 265 16.00 27.64 5 1 318 
Age 
65 and 
above 1665 147 9.65 15.28 3 1 84 
 NOAC 
Less than 65 967 133 13.50 19.03 5 1 92 
 
65 and 
above 802 78 6.85 11.52 3 1 75 
 
Warfarin 
EPO 308 43 8.07 14.47 2 1 64 
 
HMO 209 70 19.33 20.73 12.5 1 90 
Region IND 750 38 8.79 20.39 3 1 109 
 
OTH 7 5 21.20 16.13 25 1 41 
 
POS 1840 239 13.90 27.06 4 1 318 
 
PPO 171 17 11.59 18.75 6 1 72 
 
NOAC 
EPO 204 24 7.17 9.40 2.5 1 33 
 
HMO 103 21 10.67 17.79 4 1 80 
 
IND 280 21 6.43 7.53 2 1 21 
 
POS 1103 138 12.51 18.84 3 1 92 
 
PPO 79 7 10.43 12.83 7 1 37 
 Warfarin 
Low risk 435 71 14.58 18.10 5 1 87 
Chads2 
Mod-high 
risk 2850 341 13.56 25.24 4 1 318 
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 NOAC 
Low risk 278 31 10.03 13.33 2 1 44 
 
Mod-high 
risk 1491 180 11.22 17.50 3 1 92 
 
Warfarin 
CCI score 0 402 56 13.84 19.51 3 1 87 
CCI 
CCI score 1-
2 1289 165 13.21 20.08 4 1 109 
 
CCI score 3 
and+ 1594 191 14.16 28.33 5 1 318 
 
NOAC 
CCI score 0 310 39 12.26 19.41 3 1 92 
 
CCI score 1-
2 851 101 10.64 16.02 3 1 75 
 
CCI score 3 
and+ 608 71 10.94 16.97 4 1 82 
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Table 3.10 Annual Office Visits by Subgroup and Drug Class  
Subgroup  Drug Class Subgroup  N Obs N Mean 
Std 
Dev Median Min Maximum 
 
Warfarin Female 1174 1173 79.43 61.78 66 1 875 
Gender   Male 2111 2108 73.79 62.55 60 1 860 
 
NOAC 
Female 544 543 52.23 44.85 40 1 428 
 
Male 1225 1225 45.65 44.23 35 1 773 
 
Warfarin Northeast 366 366 79.24 63.79 63 1 473 
 
  Midwest 1080 1077 70.00 61.63 57 1 875 
Region   South 1225 1224 82.46 64.73 68 2 723 
 
  West 614 614 70.66 56.14 56.5 1 481 
 
NOAC 
Northeast 168 168 51.47 45.61 39 1 337 
 
Midwest 387 387 41.97 33.17 32 3 274 
 
South 908 908 48.70 45.76 38 1 773 
 
West 306 305 49.76 51.71 36 3 428 
 
Warfarin 
Less than 65 1620 1620 77.37 65.22 63 1 875 
Age 65 and above 1665 1661 74.28 59.35 60 1 481 
 
NOAC 
Less than 65 967 967 44.20 39.22 34 2 428 
 
65 and above 802 801 51.86 49.87 39 1 773 
 
Warfarin 
EPO 308 308 83.08 62.83 70 3 423 
 
HMO 209 209 90.64 98.40 68 2 875 
Region IND 750 747 70.79 52.85 58 1 323 
 
OTH 7 7 97.29 74.67 128 1 199 
 
POS 1840 1839 74.83 60.00 61 1 723 
 
PPO 171 171 76.16 63.93 63 1 473 
 
NOAC 
EPO 204 204 47.34 37.61 38 3 254 
 
HMO 103 103 46.87 30.50 41 8 170 
 
IND 280 279 55.28 48.16 41 1 296 
 
POS 1103 1103 45.27 44.42 34 2 773 
 
PPO 79 79 56.16 59.06 38 1 390 
 Warfarin 
Low risk 435 435 67.77 50.43 53 2 282 
Chads2 
Mod-high 
risk 2850 2846 77.03 63.87 62 1 875 
 
NOAC Low risk 278 278 37.38 34.10 27 2 263 
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Mod-high 
risk 1491 1490 49.59 45.95 38 1 773 
 Warfarin 
CCI score 0 402 400 63.74 48.39 51 1 391 
CCI CCI score 1-2 1289 1287 69.15 55.83 56 1 875 
 
CCI score 3 
and+ 1594 1594 84.21 68.93 67 1 860 
 
NOAC 
CCI score 0 310 310 37.38 42.22 26.5 1 428 
 
CCI score 1-2 851 850 44.32 44.71 32 2 773 
 
CCI score 3 
and+ 608 608 57.60 43.55 46 1 337 
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Table 3.11: Comparison of Annual HCRU by Adherence 
 
NOAC (Mean) Adherence (n=1388) Non Adherence (n=382) 
 
T-test p-
value 
Annual ER 10.59 (16.32) 12.68 (9.11) 0.5047 
Annual Office Visit 49.07 (46.89) 42.56 (34.10) 0.0026 
Annual Inpatient Cost 24760.67 (34102.33) 30549.13 (40547.51) 0.1038 
Annual All Cost 34854.65 (57328.97) 37821.67 (49239.30) 0.3156 
NOAC (Median) Adherence (n=1388) Non Adherence (n=382) 
p-value for 
median 
Annual ER 3 4 0.6069 
Annual Office Visit 37 34 0.1716 
Annual Inpatient Cost 15962.44 11635.74 0.0554 
Annual All Cost 18844.03 20853.42 0.4257 
*The above estimated are unadjusted 
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Table 3.12 Annual Bleeding related Drug Cost by Subgroup and Drug Class 
Subgroup  Drug  Class Category 
N 
Obs N Mean Std Dev Median Min Maximum 
 Warfarin 
Female 192 192 2740.61 7905.73 364.38 48.68 49118.13 
Gender 
Male 366 366 4259.49 23696.38 392.19 27.06 403365.50 
 
NOAC 
Female 72 72 5930.70 1995.49 5763.31 1737.75 14101.54 
 
Male 152 152 6116.05 3235.18 5784.74 923.43 28342.81 
 
Warfarin 
Northeast 65 65 4188.57 11918.79 406.60 59.41 75025.93 
 
Midwest 159 159 2315.98 7756.81 342.54 42.59 62057.99 
Region South 227 227 4714.82 29005.37 410.59 27.06 403365.50 
 
West 107 107 3499.15 8627.67 390.95 54.56 41743.37 
 
NOAC 
Northeast 16 16 6481.00 1858.66 6792.69 2509.63 8985.12 
 
Midwest 54 54 5602.66 1960.57 5416.12 2667.63 14101.54 
 
South 103 103 6273.41 3683.59 5814.43 923.43 28342.81 
 
West 51 51 5965.67 2029.72 5791.47 1737.75 13924.84 
 Warfarin 
Less than 
65 242 242 5697.99 28893.37 416.62 53.90 403365.50 
Age 
65 and 
above 316 316 2234.99 6748.45 360.69 27.06 75025.93 
 NOAC 
Less than 
65 97 97 5856.11 2925.96 5646.68 942.61 23974.32 
 
65 and 
above 127 127 6209.50 2867.54 5840.47 923.43 28342.81 
 
Warfarin 
EPO 59 59 5043.53 10451.37 399.67 80.77 43167.92 
 
HMO 35 35 1622.85 4663.52 501.27 27.06 27456.84 
Insurance IND 137 137 1985.54 4927.44 357.37 42.59 38018.60 
 
OTH 1 1 236.03 . 236.03 236.03 236.03 
 
POS 301 301 4383.01 25836.95 377.11 35.83 403365.50 
 
PPO 25 25 5570.52 15332.13 370.50 47.00 75025.93 
 
NOAC 
EPO 22 22 7430.97 6452.79 5712.34 942.61 28342.81 
 
HMO 9 9 5332.71 1595.41 5339.27 2667.12 7348.76 
 
IND 60 60 6284.54 2169.82 6033.79 923.43 15482.49 
 
POS 121 121 5836.43 2201.33 5805.15 1065.84 19296.20 
 
PPO 12 12 5157.80 2040.97 5075.56 2733.34 8985.12 
 Warfarin 
Low risk 49 49 2899.28 8084.75 419.81 53.90 49118.13 
Chads2 
Mod-high 
risk 509 509 3817.50 20524.96 380.41 27.06 403365.50 
 
NOAC Low risk 19 19 5172.08 1856.43 5357.74 1737.75 8944.33 
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Mod-high 
risk 205 205 6138.44 2959.32 5799.27 923.43 28342.81 
 
Warfarin 
CCI score 
0 38 38 734.08 1465.53 310.32 47.00 8258.32 
CCI 
CCI score 
1-2 148 148 3212.20 7586.26 416.62 48.68 43167.92 
 
CCI score 
3 and+ 372 372 4252.34 23687.12 380.50 27.06 403365.50 
 
NOAC 
CCI score 
0 21 21 5568.80 1829.57 5805.15 
1737.7
5 8944.33 
 
CCI score 
1-2 81 81 5751.04 1392.35 5840.51 
1065.8
4 9047.41 
 
CCI score 
3 and+ 122 122 6343.21 3659.25 5684.40 923.43 28342.81 
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Table 3.13 Annual Bleeding related Medical Cost by Subgroup and Drug Classes  
Subgroup  Drug Class Subgroup  
N 
Obs N Mean Std Dev Median 
Minim
um Maximum 
 
Warfarin 
Female 192 192 5189.20 12711.48 1259.24 4.07 125233.25 
Gender Male 366 366 6457.84 25461.51 1077.17 12.71 408067.70 
 
NOAC 
Female 72 72 1295.20 2121.46 614.51 11.07 11774.24 
 
Male 152 152 1951.46 4109.36 524.12 6.97 30620.42 
 
Warfarin 
Northeast 65 65 6320.01 14652.69 960.81 13.36 75747.39 
 
Midwest 159 159 5420.93 14969.78 1191.54 15.69 154998.39 
Region South 227 227 7119.20 30478.76 1292.56 4.07 408067.70 
 
West 107 107 4402.89 8677.46 747.26 12.78 42233.69 
 
NOAC 
Northeast 16 16 1212.51 1308.91 609.38 117.35 4510.60 
 
Midwest 54 54 1241.79 1823.59 566.67 32.54 9181.67 
 
South 103 103 2302.05 4865.62 482.44 11.04 30620.42 
 
West 51 51 1300.15 2066.49 632.05 6.97 11008.88 
 Warfarin 
Less than 
65 242 242 8948.33 31750.58 1262.04 4.07 408067.70 
Age 
65 and 
above 316 316 3779.75 8179.94 1061.46 12.71 75747.39 
 NOAC 
Less than 
65 97 97 1832.36 3696.29 666.25 11.07 27285.57 
 
65 and 
above 127 127 1670.37 3538.28 495.53 6.97 30620.42 
 
Warfarin 
EPO 59 59 8661.58 18820.37 1379.70 4.07 125233.25 
 
HMO 35 35 4437.42 6620.89 902.49 4.65 27540.98 
Region IND 137 137 3043.52 5578.41 917.93 13.36 38361.65 
 
OTH 1 1 98.18 . 98.18 98.18 98.18 
 
POS 301 301 7021.24 27906.40 1168.57 11.04 408067.70 
 
PPO 25 25 6524.02 15461.24 1297.58 15.69 75747.39 
 
NOAC 
EPO 22 22 4605.22 8405.55 789.95 47.64 30620.42 
 
HMO 9 9 538.57 890.17 163.39 50.54 2812.62 
 
IND 60 60 1305.04 2288.43 302.06 16.85 11598.13 
 
POS 121 121 1579.76 2678.94 625.12 6.97 18073.07 
 
PPO 12 12 1188.38 1298.64 784.22 36.60 4510.60 
 Warfarin 
Low risk 49 49 4103.06 8378.18 941.24 30.21 50078.34 
Chads2 
Mod-high 
risk 509 509 6205.98 22801.92 1157.85 4.07 408067.70 
 NOAC 
Low risk 19 19 1104.88 1808.94 541.42 16.85 8129.39 
 
Mod-high 
risk 205 205 1799.43 3720.12 565.24 6.97 30620.42 
 137 
 
 
Warfarin 
CCI score 
0 38 38 2391.12 4049.39 767.54 15.69 18659.21 
CCI 
CCI score 
1-2 148 148 4736.61 9055.30 1075.58 4.07 55204.71 
 
CCI score 
3 and+ 372 372 6903.26 26165.31 1286.70 4.65 408067.70 
 
NOAC 
CCI score 
0 21 21 1827.97 2848.54 558.27 6.97 10951.24 
 
CCI score 
1-2 81 81 1109.29 1856.28 384.86 32.53 11783.91 
 
CCI score 
3 and+ 122 122 2144.56 4453.81 695.94 11.07 30620.42 
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Table 3.14: Comparison of Annual and Monthly Bleeding related costs  
  Drug Cohort N Obs N Mean Std Dev Median Minimum Maximum 
Annual Drug 
Cost 
  
Warfarin 558 558 3736.86 19746.25 381.23 27.06 403365.50 
NOAC 224 224 6056.47 2891.79 5784.74 923.43 28342.81 
Monthly Drug  
Cost  
  
Warfarin 558 558 311.41 1645.52 31.77 2.25 33613.79 
NOAC 224 224 504.71 240.98 482.06 76.95 2361.90 
Monthly 
medical 
  
Warfarin 558 558 501.78 1826.87 93.66 0.34 34005.64 
NOAC 224 224 145.04 300.02 47.04 0.58 2551.70 
Annual 
Medical cost  
  
Warfarin 558 558 6021.32 21922.43 1123.86 4.07 408067.70 
NOAC 224 224 1740.52 3600.26 564.52 6.97 30620.42 
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APPENDICES III 
 
Appendix 3 Table 1: ICD-9 Diagnosis Codes 
 
  ICD-9 Codes  
AF Diagnosis  Atrial Fibrillation and Flutter 427.31, 427.32 
 Hypothyroidism 240.9 
CHA2DS2VASC 
Score  
Congestive heart failure 398.91, 402.01, 402.11, 402.91, 
404.03, 404.11, 404.13, 404.91, 404.93, 
and 428.x, 518.4 
Diabetes 250.x, 357.2, 362.0, and 366.41 
Hypertension 401.x, 402.x, 403.x, 404.x, and 405.x 
Stroke TIA 433,434, 435, 436 
 
Vascular disease 410,411,412, 413, 414, 443.8, 443.9 
 
Major Charlson’s 
Comorbidity Index 
diagnosis  
Myocardial Infarction 410, 412 
CHF 428 
Cerebrovascular disease  430-438 
COPD 490-496, 500-505, 506.4 
Paralysis  342, 344.1 
Chronic Renal failure 582, 585, 586, 588, 583.0 – 583.7 
Ulcers 531-534 
Cirrhodites 5712, 5714, 5715, 5716 
AIDs 042,044 
Metastatic tumor  196.0-199.1, 196.x 
INR Monitoring  Prothrombin time V58.61, CPT codes 85610, 85611, 99363, 
and 99364 
Rothendler JA, Rose AJ, Reisman JI, Berlowitz DR, Kazis LE. Choices in the use of ICD-9 codes to 
identify stroke risk factors can affect the apparent population-level risk factor prevalence and 
distribution of CHADS2 scores. American Journal of Cardiovascular Disease. 2012;2(3):184-191. 
http://healthcaredelivery.cancer.gov/seermedicare/program/charlson.comorbidity.macro.txt 
Mercaldi, Catherine J., et al. "Long-term costs of ischemic stroke and major bleeding events among 
Medicare patients with nonvalvular atrial fibrillation."Cardiology research and practice 2012 (2012). 
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